<?xml version="1.0"?>
<Ontology xmlns="http://www.w3.org/2002/07/owl#"
     xml:base="http://purl.org/OpenPVSignal/examples/WHO_UMC_Pharmacovigilance_Newsletter_2017_3_Ibrutinib_and_pneumonitis.owl"
     xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
     xmlns:xml="http://www.w3.org/XML/1998/namespace"
     xmlns:xsd="http://www.w3.org/2001/XMLSchema#"
     xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#"
     ontologyIRI="http://purl.org/OpenPVSignal/examples/WHO_UMC_Pharmacovigilance_Newsletter_2017_3_Ibrutinib_and_pneumonitis.owl"
     versionIRI="http://purl.org/OpenPVSignal/examples/WHO_UMC_Pharmacovigilance_Newsletter_2017_3_Ibrutinib_and_pneumonitis,owl#draft-v0.1">
    <Prefix name="" IRI="http://purl.org/OpenPVSignal/examples/WHO_UMC_Pharmacovigilance_Newsletter_2017_3_Ibrutinib_and_pneumonitis.owl"/>
    <Prefix name="mp" IRI="http://purl.org/mp/"/>
    <Prefix name="oa#" IRI="http://www.w3.org/ns/oa#"/>
    <Prefix name="owl" IRI="http://www.w3.org/2002/07/owl#"/>
    <Prefix name="rdf" IRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#"/>
    <Prefix name="xml" IRI="http://www.w3.org/XML/1998/namespace"/>
    <Prefix name="xsd" IRI="http://www.w3.org/2001/XMLSchema#"/>
    <Prefix name="rdfs" IRI="http://www.w3.org/2000/01/rdf-schema#"/>
    <Prefix name="open-pv" IRI="http://purl.org/OpenPVSignal/OpenPVSignal.owl#"/>
    <Prefix name="time#2016" IRI="http://www.w3.org/2006/time#2016#"/>
    <Prefix name="prov-o-20130430" IRI="http://www.w3.org/ns/prov-o-20130430#"/>
    <Import>http://purl.org/OpenPVSignal/OpenPVSignal.owl</Import>
    <Annotation>
        <AnnotationProperty abbreviatedIRI="owl:versionInfo"/>
        <Literal datatypeIRI="http://www.w3.org/2000/01/rdf-schema#Literal">draft-v0.1-20171109</Literal>
    </Annotation>
    <Annotation>
        <AnnotationProperty abbreviatedIRI="rdfs:comment"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">Example of applying OpenPVSignal model on publishing information originally published in a WHO UMC report. This example uses information published on http://apps.who.int/iris/bitstream/10665/258799/1/WPN-2017-03-eng.pdf?ua=1, also accessible through http://www.who.int/medicines/publications/PharmaNewsletter3_17/en/.</Literal>
    </Annotation>
    <Annotation>
        <AnnotationProperty abbreviatedIRI="rdfs:isDefinedBy"/>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#anyURI">http://apps.who.int/iris/bitstream/10665/258799/1/WPN-2017-03-eng.pdf?ua=1</Literal>
    </Annotation>
    <Annotation>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">Second example of OpenPVSignal application (WHO UMC)</Literal>
    </Annotation>
    <Declaration>
        <NamedIndividual IRI="#Ibrutinib"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Ibrutinib_dosage_for_report_11"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Erythropoietin"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Literature_and_Labelling"/>
    </Declaration>
    <Declaration>
        <DataProperty abbreviatedIRI="open-pv:has_creation_date"/>
    </Declaration>
    <Declaration>
        <Class abbreviatedIRI="open-pv:Drug_Usage"/>
    </Declaration>
    <Declaration>
        <ObjectProperty abbreviatedIRI="open-pv:time_to_onset"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Report_2"/>
    </Declaration>
    <Declaration>
        <Class abbreviatedIRI="open-pv:Introduction"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Patient_8"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Acetylsalicylic_Acid"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Hepatotoxicity"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Tamsulosin"/>
    </Declaration>
    <Declaration>
        <DataProperty abbreviatedIRI="open-pv:has_average_age"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Follicular_lymphoma"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Uppsala_Monitoring_Centre"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Report_10"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#onset_time_for_report_1"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Myalgia"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Annotation_for_warning_regarding_pkis_and_pneumonitis"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Sepsis"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Pioglitazone"/>
    </Declaration>
    <Declaration>
        <Class abbreviatedIRI="open-pv:Warning"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Report_3"/>
    </Declaration>
    <Declaration>
        <Class abbreviatedIRI="open-pv:Signal"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Patient_9"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Sodium_decreased"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Cough"/>
    </Declaration>
    <Declaration>
        <ObjectProperty abbreviatedIRI="open-pv:concerns_indication_for_use"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Introduction"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Pneumonia"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Report_11"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Italy"/>
    </Declaration>
    <Declaration>
        <DataProperty abbreviatedIRI="open-pv:has_age"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#reports_having_MCL_as_indication"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#pkis_and_hypertension"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Ibrutinib_dosage_4_for_report_7"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_2"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Patient_6"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Rhinovirus_infection"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Anemia"/>
    </Declaration>
    <Declaration>
        <ObjectProperty IRI="http://www.w3.org/ns/prov#atLocation"/>
    </Declaration>
    <Declaration>
        <DataProperty abbreviatedIRI="open-pv:concerns_action_upon_adverse_effect"/>
    </Declaration>
    <Declaration>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_signal"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#7._Mato_AR,_Islam_P,_Daniel_C,_Strelec_L,_Kaye_AH,_Brooks_S,_et_al._Ibrutinib-induced_pneumonitis_in_patients_with_chronic_lymphocytic_leukemia._Blood,_2016._Feb_25;127(8):1064-7."/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Arthralgia"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Respiratory_failure"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Patient_11"/>
    </Declaration>
    <Declaration>
        <Class abbreviatedIRI="open-pv:Free_text_reporting_element"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Ibrutinib_and_pneumonitis_UMC_WHO_report"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Report_1"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Pneumonitis"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Ibrutinib_dosage_3_for_report_7"/>
    </Declaration>
    <Declaration>
        <ObjectProperty abbreviatedIRI="open-pv:is_related_with_primary_suspect_drug"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_3"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Patient_7"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Ibrutinib_dosage_for_report_12"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Ibrutinib_dosage_2_for_report_9"/>
    </Declaration>
    <Declaration>
        <ObjectProperty abbreviatedIRI="open-pv:is_subgroup_of"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#reports_with_negative_rechallenge"/>
    </Declaration>
    <Declaration>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_class"/>
    </Declaration>
    <Declaration>
        <DataProperty IRI="http://www.w3.org/2006/time#days"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#6._Electronic_Medicines_Compendium:_Summary_of_Product_Characteristics_for_filgrastim_(Neupogen®)._Available_from:_https://www.medicines.org.uk/emc/_medicine/27485._Accessed:_October_2016."/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#USA"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Patient_10"/>
    </Declaration>
    <Declaration>
        <Class abbreviatedIRI="open-pv:Clinical_trial_information"/>
    </Declaration>
    <Declaration>
        <Class abbreviatedIRI="open-pv:Conclusion"/>
    </Declaration>
    <Declaration>
        <ObjectProperty abbreviatedIRI="oa#:hasSelector"/>
    </Declaration>
    <Declaration>
        <DataProperty abbreviatedIRI="open-pv:has_content"/>
    </Declaration>
    <Declaration>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_drug"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Report_6"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#United_Kingdom"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_4"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Pyrexia"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Rosuvastatin"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Editorial_Comment"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Selector_1"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#mantle_cell_lymphoma_(MCL)"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Overall_reports_in_Vigibase"/>
    </Declaration>
    <Declaration>
        <Class abbreviatedIRI="open-pv:Indication"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#pkis_and_hepatotoxicity"/>
    </Declaration>
    <Declaration>
        <ObjectProperty abbreviatedIRI="mp:references"/>
    </Declaration>
    <Declaration>
        <Class abbreviatedIRI="open-pv:Author"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_5"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Ibrutinib_dosage_5_for_report_7"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Reports_in_VigiBase"/>
    </Declaration>
    <Declaration>
        <ObjectProperty abbreviatedIRI="open-pv:is_related_with_concomitant_drug"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Dr_Birgitta_Grundmark"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#3._European_Medicines_Agency:_Summary_of_Product_Characteristics_for_everolimus_(Afinitor®)._Available_from:_http://www.ema.europa.eu/docs/en_GB/_document_library/EPAR_-_Product_Information/_human/001038/WC500022814.pdf._Accessed:_October_2016."/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Warfarin"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Report_7"/>
    </Declaration>
    <Declaration>
        <DataProperty abbreviatedIRI="open-pv:has_max_age"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Valaciclovir"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Patient_5"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Mato_cases_description"/>
    </Declaration>
    <Declaration>
        <DataProperty abbreviatedIRI="open-pv:has_gender"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Bone_pain"/>
    </Declaration>
    <Declaration>
        <Class abbreviatedIRI="open-pv:ADR_Mechanism"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Electrolyte_disturbances"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#one_day_interval_between_administrations"/>
    </Declaration>
    <Declaration>
        <Datatype abbreviatedIRI="xsd:gYearMonth"/>
    </Declaration>
    <Declaration>
        <DataProperty abbreviatedIRI="oa#:exact"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#5._Electronic_Medicines_Compendium:_Summary_of_Product_Characteristics_for_mesalazine_(Asacol®)._Available_from:_https://www.medicines.org.uk/emc/_medicine/20478._Accessed:_October_2016."/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Ibrutinib_dosage_for_report_5"/>
    </Declaration>
    <Declaration>
        <DataProperty abbreviatedIRI="open-pv:has_min_age"/>
    </Declaration>
    <Declaration>
        <Class abbreviatedIRI="open-pv:DrugClass"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Patient_2"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://www.w3.org/ns/prov#Location"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Report_4"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Tranexamic_acid"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Metformin"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Amlodipine"/>
    </Declaration>
    <Declaration>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_dosage"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Aminophylline"/>
    </Declaration>
    <Declaration>
        <Class abbreviatedIRI="open-pv:Mechanism"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#2._European_Medicines_Agency:_Summary_of_Product_Characteristics_for_rituximab_(MabThera®)._Available_from:_http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000165/WC500025821.pdf._Accessed:_October_2016."/>
    </Declaration>
    <Declaration>
        <DataProperty abbreviatedIRI="open-pv:has_count_of_men"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Germany"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_7"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Furosemide"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Patient_3"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Levothyroxine"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Rituximab"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://www.w3.org/ns/prov#Organization"/>
    </Declaration>
    <Declaration>
        <AnnotationProperty abbreviatedIRI="oa#:hasBody"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Report_5"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Peripheral_swelling"/>
    </Declaration>
    <Declaration>
        <Class abbreviatedIRI="open-pv:Literature_information"/>
    </Declaration>
    <Declaration>
        <DataProperty abbreviatedIRI="open-pv:has_reporter_type"/>
    </Declaration>
    <Declaration>
        <DataProperty abbreviatedIRI="open-pv:has_subject"/>
    </Declaration>
    <Declaration>
        <Class abbreviatedIRI="open-pv:Drug"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#ibrutinib_mechanism"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Acute_Respiratory_Distress_Syndrome"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Ibrutinib_dosage_for_report_4"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#onset_time_for_report_11"/>
    </Declaration>
    <Declaration>
        <ObjectProperty abbreviatedIRI="open-pv:has_mechanism"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_8"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Aciclovir"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Fatigue"/>
    </Declaration>
    <Declaration>
        <DataProperty abbreviatedIRI="open-pv:refers_to_rechallenge_outcome"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Insulin"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#protein_kinase_inhibitors"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Ibrutinib_dosage_1_for_report_7"/>
    </Declaration>
    <Declaration>
        <Class abbreviatedIRI="open-pv:Bibliographic_reference"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#onset_time_for_report_9"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#8._Shah_RR._Tyrosine_Kinase_Inhibitor-Induced_Interstitial_Lung_Disease:_Clinical_Features,_Diagnostic_Challenges,_and_Therapeutic_Dilemmas._Drug_Saf._2016_Aug_17._[Epub_ahead_of_print]."/>
    </Declaration>
    <Declaration>
        <AnnotationProperty abbreviatedIRI="oa#:hasTarget"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Colecalciferol"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#pkis_and_electrolytes"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Ibrutinib_dosage_for_report_3"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#onset_time_for_report_12"/>
    </Declaration>
    <Declaration>
        <DataProperty abbreviatedIRI="open-pv:refers_to_database"/>
    </Declaration>
    <Declaration>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_adverse_effect"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#9._Mahmoudi_M,_Murthy_V,_Suh_J,_Bradshaw_A,_Sloance_M._Ibrutinib-Induced_Rapidly_Progressive_Inflammatory_Pneumonitis._American_Thoracic_Society_International_Conference_Abstract,_2015."/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_9"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Nasopharyngitis"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Patient_1"/>
    </Declaration>
    <Declaration>
        <DataProperty abbreviatedIRI="open-pv:has_first_name"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Diarrhea"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#pkis_and_cardiotoxicity"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#ibrutinib_ADR_mechanism"/>
    </Declaration>
    <Declaration>
        <ObjectProperty abbreviatedIRI="open-pv:is_supported_by_spontaneous_report"/>
    </Declaration>
    <Declaration>
        <Class IRI="#Less_than_7_months"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Ezetimibe"/>
    </Declaration>
    <Declaration>
        <Class abbreviatedIRI="oa#:TextQuoteSelector"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Ω-3-acid"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Nifedipine"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#reports_from_UK"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Nausea"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Filgrastim"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Metoprolol"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Ibrutinib_dosage_for_report_2"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Pleural_effusion"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#pkis_and_pneumonitis"/>
    </Declaration>
    <Declaration>
        <DataProperty abbreviatedIRI="open-pv:has_last_name"/>
    </Declaration>
    <Declaration>
        <Class abbreviatedIRI="open-pv:VigiBase_Report"/>
    </Declaration>
    <Declaration>
        <Class IRI="http://www.w3.org/2006/time#DurationDescription"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Muscle_spasms"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Report_8"/>
    </Declaration>
    <Declaration>
        <Class abbreviatedIRI="oa#:Annotation"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#reports_having_CLL_as_indication"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#signal_in_the_report"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Pulmonary_fibrosis"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Ibrutinib_dosage_1_for_report_9"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#onset_time_for_report_7"/>
    </Declaration>
    <Declaration>
        <Class abbreviatedIRI="open-pv:ADR_Signal_Report"/>
    </Declaration>
    <Declaration>
        <DataProperty abbreviatedIRI="open-pv:has_count_of_women"/>
    </Declaration>
    <Declaration>
        <Class abbreviatedIRI="open-pv:Summary"/>
    </Declaration>
    <Declaration>
        <DataProperty abbreviatedIRI="oa#:prefix"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#ibrutinib_metabolism"/>
    </Declaration>
    <Declaration>
        <DataProperty abbreviatedIRI="open-pv:has_affiliation"/>
    </Declaration>
    <Declaration>
        <DataProperty abbreviatedIRI="open-pv:has_median_age"/>
    </Declaration>
    <Declaration>
        <DataProperty abbreviatedIRI="open-pv:refers_to_rechallenge_process"/>
    </Declaration>
    <Declaration>
        <ObjectProperty abbreviatedIRI="open-pv:is_part_of"/>
    </Declaration>
    <Declaration>
        <Datatype abbreviatedIRI="xsd:date"/>
    </Declaration>
    <Declaration>
        <DataProperty abbreviatedIRI="open-pv:refers_to_dechallenge_outcome"/>
    </Declaration>
    <Declaration>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_patient"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Allopurinol"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Report_9"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Acute_kidney_injure"/>
    </Declaration>
    <Declaration>
        <Class abbreviatedIRI="open-pv:Case_narrative"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#pkis_and_pneumonia"/>
    </Declaration>
    <Declaration>
        <DataProperty abbreviatedIRI="open-pv:has_count"/>
    </Declaration>
    <Declaration>
        <ObjectProperty abbreviatedIRI="open-pv:is_supported_by_statistical_entity"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Cardiotoxicity"/>
    </Declaration>
    <Declaration>
        <AnnotationProperty abbreviatedIRI="oa#:hasSource"/>
    </Declaration>
    <Declaration>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_interval_between_administrations"/>
    </Declaration>
    <Declaration>
        <DataProperty IRI="http://www.w3.org/2006/time#months"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Oxycodone"/>
    </Declaration>
    <Declaration>
        <DataProperty abbreviatedIRI="open-pv:refers_to_dechallenge_process"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Ibrutinib_dosage_2_for_report_7"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Atrial_Fibrillation"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Discussion_and_Conclusion"/>
    </Declaration>
    <Declaration>
        <DataProperty abbreviatedIRI="oa#:suffix"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#chronic_lymphatic_leukaemia_(CLL)"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Congestive_cardiac_failure"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#onset_time_for_report_5"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_10"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#4._US_Food_and_Drug_Administration:_Product_label_for_bendamustine_(Treanda®)._Available_from:_http://www.accessdata.fda.gov/drugsatfda__docs/label/2016/022249s022lbl.pdf._Accessed:_October_2016."/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#reports_having_fatal_outcome"/>
    </Declaration>
    <Declaration>
        <ObjectProperty abbreviatedIRI="open-pv:is_related_with_secondary_suspect_drug"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Toxicity"/>
    </Declaration>
    <Declaration>
        <DataProperty abbreviatedIRI="open-pv:refers_to_dosage_value"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Enoxaparin"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Bendamustine"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#reports_having_ibrutinib_as_primary_suspect_drug"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#1._European_Medicines_Agency:_Summary_of_Product_Characteristics_for_ibrutinib_(Imbruvica®)._Available_from:_http://www.ema.europa.eu/docs/en_GB/_document_library/EPAR_-_Product_Information/_human/003791/WC500177775.pdf._Accessed:_September_2016."/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#reports_dechallenged_having_recovery_as_outcome"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#reports_from_USA"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Patient_12"/>
    </Declaration>
    <Declaration>
        <DataProperty abbreviatedIRI="open-pv:refers_to_outcome_after_action"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#onset_time_for_report_4"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_11"/>
    </Declaration>
    <Declaration>
        <Class abbreviatedIRI="open-pv:Adverse_Effect"/>
    </Declaration>
    <Declaration>
        <ObjectProperty abbreviatedIRI="open-pv:hasClass"/>
    </Declaration>
    <Declaration>
        <Class abbreviatedIRI="open-pv:Structured_Product_Labels_information"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Chloramphenicol"/>
    </Declaration>
    <Declaration>
        <Class abbreviatedIRI="open-pv:Reports_group"/>
    </Declaration>
    <Declaration>
        <ObjectProperty abbreviatedIRI="mp:publishedBy"/>
    </Declaration>
    <Declaration>
        <Class abbreviatedIRI="open-pv:Dosage"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Prednisone"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#reports_from_Italy"/>
    </Declaration>
    <Declaration>
        <DataProperty abbreviatedIRI="open-pv:has_overall_conclusion"/>
    </Declaration>
    <Declaration>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_reported_drug_usage"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#reports_from_Germany"/>
    </Declaration>
    <Declaration>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_author"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_12"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#onset_time_for_report_3"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Report_12"/>
    </Declaration>
    <Declaration>
        <DataProperty IRI="http://www.w3.org/2006/time#weeks"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Pantoprazole"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Swelling"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Waldenström’s_macroglobulinaemia_(WM)"/>
    </Declaration>
    <Declaration>
        <Class IRI="#More_than_4_months"/>
    </Declaration>
    <Declaration>
        <Class abbreviatedIRI="open-pv:Patient"/>
    </Declaration>
    <Declaration>
        <DataProperty abbreviatedIRI="open-pv:initially_identified_on"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Summary"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#Hypertension"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#onset_time_for_report_2"/>
    </Declaration>
    <Declaration>
        <NamedIndividual IRI="#onset_time_for_report_10"/>
    </Declaration>
    <Declaration>
        <ObjectProperty abbreviatedIRI="mp:referencedBy"/>
    </Declaration>
    <SubClassOf>
        <Class IRI="#Less_than_7_months"/>
        <Class IRI="http://www.w3.org/2006/time#DurationDescription"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#Less_than_7_months"/>
        <DataSomeValuesFrom>
            <DataProperty IRI="http://www.w3.org/2006/time#months"/>
            <DatatypeRestriction>
                <Datatype abbreviatedIRI="xsd:integer"/>
                <FacetRestriction facet="http://www.w3.org/2001/XMLSchema#maxExclusive">
                    <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">7</Literal>
                </FacetRestriction>
            </DatatypeRestriction>
        </DataSomeValuesFrom>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#More_than_4_months"/>
        <Class IRI="http://www.w3.org/2006/time#DurationDescription"/>
    </SubClassOf>
    <SubClassOf>
        <Class IRI="#More_than_4_months"/>
        <DataSomeValuesFrom>
            <DataProperty IRI="http://www.w3.org/2006/time#months"/>
            <DatatypeRestriction>
                <Datatype abbreviatedIRI="xsd:integer"/>
                <FacetRestriction facet="http://www.w3.org/2001/XMLSchema#minExclusive">
                    <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">4</Literal>
                </FacetRestriction>
            </DatatypeRestriction>
        </DataSomeValuesFrom>
    </SubClassOf>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Drug"/>
        <NamedIndividual IRI="#Acetylsalicylic_Acid"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Drug"/>
        <NamedIndividual IRI="#Aciclovir"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Adverse_Effect"/>
        <NamedIndividual IRI="#Acute_Respiratory_Distress_Syndrome"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Adverse_Effect"/>
        <NamedIndividual IRI="#Acute_kidney_injure"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Drug"/>
        <NamedIndividual IRI="#Allopurinol"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Drug"/>
        <NamedIndividual IRI="#Aminophylline"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Drug"/>
        <NamedIndividual IRI="#Amlodipine"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Adverse_Effect"/>
        <NamedIndividual IRI="#Anemia"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="oa#:Annotation"/>
        <NamedIndividual IRI="#Annotation_for_warning_regarding_pkis_and_pneumonitis"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Adverse_Effect"/>
        <NamedIndividual IRI="#Arthralgia"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Adverse_Effect"/>
        <NamedIndividual IRI="#Atrial_Fibrillation"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Drug"/>
        <NamedIndividual IRI="#Bendamustine"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Adverse_Effect"/>
        <NamedIndividual IRI="#Bone_pain"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Adverse_Effect"/>
        <NamedIndividual IRI="#Cardiotoxicity"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Drug"/>
        <NamedIndividual IRI="#Chloramphenicol"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Drug"/>
        <NamedIndividual IRI="#Colecalciferol"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Adverse_Effect"/>
        <NamedIndividual IRI="#Congestive_cardiac_failure"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Adverse_Effect"/>
        <NamedIndividual IRI="#Cough"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Adverse_Effect"/>
        <NamedIndividual IRI="#Diarrhea"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Conclusion"/>
        <NamedIndividual IRI="#Discussion_and_Conclusion"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Author"/>
        <NamedIndividual IRI="#Dr_Birgitta_Grundmark"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Free_text_reporting_element"/>
        <NamedIndividual IRI="#Editorial_Comment"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Adverse_Effect"/>
        <NamedIndividual IRI="#Electrolyte_disturbances"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Drug"/>
        <NamedIndividual IRI="#Enoxaparin"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Drug"/>
        <NamedIndividual IRI="#Erythropoietin"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Drug"/>
        <NamedIndividual IRI="#Ezetimibe"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Adverse_Effect"/>
        <NamedIndividual IRI="#Fatigue"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Drug"/>
        <NamedIndividual IRI="#Filgrastim"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Indication"/>
        <NamedIndividual IRI="#Follicular_lymphoma"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Drug"/>
        <NamedIndividual IRI="#Furosemide"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class IRI="http://www.w3.org/ns/prov#Location"/>
        <NamedIndividual IRI="#Germany"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Adverse_Effect"/>
        <NamedIndividual IRI="#Hepatotoxicity"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Adverse_Effect"/>
        <NamedIndividual IRI="#Hypertension"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Drug"/>
        <NamedIndividual IRI="#Ibrutinib"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:ADR_Signal_Report"/>
        <NamedIndividual IRI="#Ibrutinib_and_pneumonitis_UMC_WHO_report"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Dosage"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_1_for_report_7"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Dosage"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_1_for_report_9"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Dosage"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_2_for_report_7"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Dosage"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_2_for_report_9"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Dosage"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_3_for_report_7"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Dosage"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_4_for_report_7"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Dosage"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_5_for_report_7"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Dosage"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_for_report_11"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Dosage"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_for_report_12"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Dosage"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_for_report_2"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Dosage"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_for_report_3"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Dosage"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_for_report_4"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Dosage"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_for_report_5"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Drug_Usage"/>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_10"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Drug_Usage"/>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_11"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Drug_Usage"/>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_12"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Drug_Usage"/>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_2"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Drug_Usage"/>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_3"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Drug_Usage"/>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_4"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Drug_Usage"/>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_5"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Drug_Usage"/>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_7"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Drug_Usage"/>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_8"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Drug_Usage"/>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_9"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Drug"/>
        <NamedIndividual IRI="#Insulin"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Introduction"/>
        <NamedIndividual IRI="#Introduction"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class IRI="http://www.w3.org/ns/prov#Location"/>
        <NamedIndividual IRI="#Italy"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Drug"/>
        <NamedIndividual IRI="#Levothyroxine"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Literature_information"/>
        <NamedIndividual IRI="#Literature_and_Labelling"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Structured_Product_Labels_information"/>
        <NamedIndividual IRI="#Literature_and_Labelling"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Case_narrative"/>
        <NamedIndividual IRI="#Mato_cases_description"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Drug"/>
        <NamedIndividual IRI="#Metformin"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Drug"/>
        <NamedIndividual IRI="#Metoprolol"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Adverse_Effect"/>
        <NamedIndividual IRI="#Muscle_spasms"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Adverse_Effect"/>
        <NamedIndividual IRI="#Myalgia"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Adverse_Effect"/>
        <NamedIndividual IRI="#Nasopharyngitis"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Adverse_Effect"/>
        <NamedIndividual IRI="#Nausea"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Drug"/>
        <NamedIndividual IRI="#Nifedipine"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Reports_group"/>
        <NamedIndividual IRI="#Overall_reports_in_Vigibase"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Drug"/>
        <NamedIndividual IRI="#Oxycodone"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Drug"/>
        <NamedIndividual IRI="#Pantoprazole"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Patient"/>
        <NamedIndividual IRI="#Patient_1"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Patient"/>
        <NamedIndividual IRI="#Patient_10"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Patient"/>
        <NamedIndividual IRI="#Patient_11"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Patient"/>
        <NamedIndividual IRI="#Patient_12"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Patient"/>
        <NamedIndividual IRI="#Patient_2"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Patient"/>
        <NamedIndividual IRI="#Patient_3"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Patient"/>
        <NamedIndividual IRI="#Patient_5"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Patient"/>
        <NamedIndividual IRI="#Patient_6"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Patient"/>
        <NamedIndividual IRI="#Patient_7"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Patient"/>
        <NamedIndividual IRI="#Patient_8"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Patient"/>
        <NamedIndividual IRI="#Patient_9"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Adverse_Effect"/>
        <NamedIndividual IRI="#Peripheral_swelling"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Drug"/>
        <NamedIndividual IRI="#Pioglitazone"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Adverse_Effect"/>
        <NamedIndividual IRI="#Pleural_effusion"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Adverse_Effect"/>
        <NamedIndividual IRI="#Pneumonia"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Adverse_Effect"/>
        <NamedIndividual IRI="#Pneumonitis"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Drug"/>
        <NamedIndividual IRI="#Prednisone"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Adverse_Effect"/>
        <NamedIndividual IRI="#Pulmonary_fibrosis"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Adverse_Effect"/>
        <NamedIndividual IRI="#Pyrexia"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:VigiBase_Report"/>
        <NamedIndividual IRI="#Report_1"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:VigiBase_Report"/>
        <NamedIndividual IRI="#Report_10"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:VigiBase_Report"/>
        <NamedIndividual IRI="#Report_11"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:VigiBase_Report"/>
        <NamedIndividual IRI="#Report_12"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Clinical_trial_information"/>
        <NamedIndividual IRI="#Report_2"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:VigiBase_Report"/>
        <NamedIndividual IRI="#Report_2"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:VigiBase_Report"/>
        <NamedIndividual IRI="#Report_3"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:VigiBase_Report"/>
        <NamedIndividual IRI="#Report_4"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:VigiBase_Report"/>
        <NamedIndividual IRI="#Report_5"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:VigiBase_Report"/>
        <NamedIndividual IRI="#Report_6"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:VigiBase_Report"/>
        <NamedIndividual IRI="#Report_7"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:VigiBase_Report"/>
        <NamedIndividual IRI="#Report_8"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:VigiBase_Report"/>
        <NamedIndividual IRI="#Report_9"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Free_text_reporting_element"/>
        <NamedIndividual IRI="#Reports_in_VigiBase"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Adverse_Effect"/>
        <NamedIndividual IRI="#Respiratory_failure"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Adverse_Effect"/>
        <NamedIndividual IRI="#Rhinovirus_infection"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Drug"/>
        <NamedIndividual IRI="#Rituximab"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Drug"/>
        <NamedIndividual IRI="#Rosuvastatin"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="oa#:TextQuoteSelector"/>
        <NamedIndividual IRI="#Selector_1"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Adverse_Effect"/>
        <NamedIndividual IRI="#Sepsis"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Adverse_Effect"/>
        <NamedIndividual IRI="#Sodium_decreased"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Summary"/>
        <NamedIndividual IRI="#Summary"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Adverse_Effect"/>
        <NamedIndividual IRI="#Swelling"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Drug"/>
        <NamedIndividual IRI="#Tamsulosin"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Adverse_Effect"/>
        <NamedIndividual IRI="#Toxicity"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Drug"/>
        <NamedIndividual IRI="#Tranexamic_acid"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class IRI="http://www.w3.org/ns/prov#Location"/>
        <NamedIndividual IRI="#USA"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class IRI="http://www.w3.org/ns/prov#Location"/>
        <NamedIndividual IRI="#United_Kingdom"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class IRI="http://www.w3.org/ns/prov#Organization"/>
        <NamedIndividual IRI="#Uppsala_Monitoring_Centre"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Drug"/>
        <NamedIndividual IRI="#Valaciclovir"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Drug"/>
        <NamedIndividual IRI="#Warfarin"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:ADR_Mechanism"/>
        <NamedIndividual IRI="#ibrutinib_ADR_mechanism"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Mechanism"/>
        <NamedIndividual IRI="#ibrutinib_mechanism"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Mechanism"/>
        <NamedIndividual IRI="#ibrutinib_metabolism"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Warning"/>
        <NamedIndividual IRI="#ibrutinib_metabolism"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class IRI="http://www.w3.org/2006/time#DurationDescription"/>
        <NamedIndividual IRI="#one_day_interval_between_administrations"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class IRI="#Less_than_7_months"/>
        <NamedIndividual IRI="#onset_time_for_report_1"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class IRI="#More_than_4_months"/>
        <NamedIndividual IRI="#onset_time_for_report_10"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class IRI="http://www.w3.org/2006/time#DurationDescription"/>
        <NamedIndividual IRI="#onset_time_for_report_11"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class IRI="http://www.w3.org/2006/time#DurationDescription"/>
        <NamedIndividual IRI="#onset_time_for_report_12"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class IRI="http://www.w3.org/2006/time#DurationDescription"/>
        <NamedIndividual IRI="#onset_time_for_report_2"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class IRI="http://www.w3.org/2006/time#DurationDescription"/>
        <NamedIndividual IRI="#onset_time_for_report_3"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class IRI="http://www.w3.org/2006/time#DurationDescription"/>
        <NamedIndividual IRI="#onset_time_for_report_4"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class IRI="http://www.w3.org/2006/time#DurationDescription"/>
        <NamedIndividual IRI="#onset_time_for_report_5"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class IRI="http://www.w3.org/2006/time#DurationDescription"/>
        <NamedIndividual IRI="#onset_time_for_report_7"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class IRI="http://www.w3.org/2006/time#DurationDescription"/>
        <NamedIndividual IRI="#onset_time_for_report_9"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Warning"/>
        <NamedIndividual IRI="#pkis_and_cardiotoxicity"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Warning"/>
        <NamedIndividual IRI="#pkis_and_electrolytes"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Warning"/>
        <NamedIndividual IRI="#pkis_and_hepatotoxicity"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Warning"/>
        <NamedIndividual IRI="#pkis_and_hypertension"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Warning"/>
        <NamedIndividual IRI="#pkis_and_pneumonia"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Warning"/>
        <NamedIndividual IRI="#pkis_and_pneumonitis"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:DrugClass"/>
        <NamedIndividual IRI="#protein_kinase_inhibitors"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Reports_group"/>
        <NamedIndividual IRI="#reports_dechallenged_having_recovery_as_outcome"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Reports_group"/>
        <NamedIndividual IRI="#reports_from_Germany"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Reports_group"/>
        <NamedIndividual IRI="#reports_from_Italy"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Reports_group"/>
        <NamedIndividual IRI="#reports_from_UK"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Reports_group"/>
        <NamedIndividual IRI="#reports_from_USA"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Reports_group"/>
        <NamedIndividual IRI="#reports_having_CLL_as_indication"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Reports_group"/>
        <NamedIndividual IRI="#reports_having_MCL_as_indication"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Reports_group"/>
        <NamedIndividual IRI="#reports_having_fatal_outcome"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Reports_group"/>
        <NamedIndividual IRI="#reports_having_ibrutinib_as_primary_suspect_drug"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Reports_group"/>
        <NamedIndividual IRI="#reports_with_negative_rechallenge"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Signal"/>
        <NamedIndividual IRI="#signal_in_the_report"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Drug"/>
        <NamedIndividual IRI="#Ω-3-acid"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Bibliographic_reference"/>
        <NamedIndividual IRI="#1._European_Medicines_Agency:_Summary_of_Product_Characteristics_for_ibrutinib_(Imbruvica®)._Available_from:_http://www.ema.europa.eu/docs/en_GB/_document_library/EPAR_-_Product_Information/_human/003791/WC500177775.pdf._Accessed:_September_2016."/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Bibliographic_reference"/>
        <NamedIndividual IRI="#2._European_Medicines_Agency:_Summary_of_Product_Characteristics_for_rituximab_(MabThera®)._Available_from:_http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000165/WC500025821.pdf._Accessed:_October_2016."/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Bibliographic_reference"/>
        <NamedIndividual IRI="#3._European_Medicines_Agency:_Summary_of_Product_Characteristics_for_everolimus_(Afinitor®)._Available_from:_http://www.ema.europa.eu/docs/en_GB/_document_library/EPAR_-_Product_Information/_human/001038/WC500022814.pdf._Accessed:_October_2016."/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Bibliographic_reference"/>
        <NamedIndividual IRI="#4._US_Food_and_Drug_Administration:_Product_label_for_bendamustine_(Treanda®)._Available_from:_http://www.accessdata.fda.gov/drugsatfda__docs/label/2016/022249s022lbl.pdf._Accessed:_October_2016."/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Bibliographic_reference"/>
        <NamedIndividual IRI="#5._Electronic_Medicines_Compendium:_Summary_of_Product_Characteristics_for_mesalazine_(Asacol®)._Available_from:_https://www.medicines.org.uk/emc/_medicine/20478._Accessed:_October_2016."/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Bibliographic_reference"/>
        <NamedIndividual IRI="#6._Electronic_Medicines_Compendium:_Summary_of_Product_Characteristics_for_filgrastim_(Neupogen®)._Available_from:_https://www.medicines.org.uk/emc/_medicine/27485._Accessed:_October_2016."/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Bibliographic_reference"/>
        <NamedIndividual IRI="#7._Mato_AR,_Islam_P,_Daniel_C,_Strelec_L,_Kaye_AH,_Brooks_S,_et_al._Ibrutinib-induced_pneumonitis_in_patients_with_chronic_lymphocytic_leukemia._Blood,_2016._Feb_25;127(8):1064-7."/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Bibliographic_reference"/>
        <NamedIndividual IRI="#8._Shah_RR._Tyrosine_Kinase_Inhibitor-Induced_Interstitial_Lung_Disease:_Clinical_Features,_Diagnostic_Challenges,_and_Therapeutic_Dilemmas._Drug_Saf._2016_Aug_17._[Epub_ahead_of_print]."/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Bibliographic_reference"/>
        <NamedIndividual IRI="#9._Mahmoudi_M,_Murthy_V,_Suh_J,_Bradshaw_A,_Sloance_M._Ibrutinib-Induced_Rapidly_Progressive_Inflammatory_Pneumonitis._American_Thoracic_Society_International_Conference_Abstract,_2015."/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Indication"/>
        <NamedIndividual IRI="#Waldenström’s_macroglobulinaemia_(WM)"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Indication"/>
        <NamedIndividual IRI="#chronic_lymphatic_leukaemia_(CLL)"/>
    </ClassAssertion>
    <ClassAssertion>
        <Class abbreviatedIRI="open-pv:Indication"/>
        <NamedIndividual IRI="#mantle_cell_lymphoma_(MCL)"/>
    </ClassAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_related_with_concomitant_drug"/>
        <NamedIndividual IRI="#Furosemide"/>
        <NamedIndividual IRI="#Furosemide"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:hasClass"/>
        <NamedIndividual IRI="#Ibrutinib"/>
        <NamedIndividual IRI="#protein_kinase_inhibitors"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:has_mechanism"/>
        <NamedIndividual IRI="#Ibrutinib"/>
        <NamedIndividual IRI="#ibrutinib_ADR_mechanism"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:has_mechanism"/>
        <NamedIndividual IRI="#Ibrutinib"/>
        <NamedIndividual IRI="#ibrutinib_mechanism"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:has_mechanism"/>
        <NamedIndividual IRI="#Ibrutinib"/>
        <NamedIndividual IRI="#ibrutinib_metabolism"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_author"/>
        <NamedIndividual IRI="#Ibrutinib_and_pneumonitis_UMC_WHO_report"/>
        <NamedIndividual IRI="#Dr_Birgitta_Grundmark"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_signal"/>
        <NamedIndividual IRI="#Ibrutinib_and_pneumonitis_UMC_WHO_report"/>
        <NamedIndividual IRI="#signal_in_the_report"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="mp:publishedBy"/>
        <NamedIndividual IRI="#Ibrutinib_and_pneumonitis_UMC_WHO_report"/>
        <NamedIndividual IRI="#Uppsala_Monitoring_Centre"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_interval_between_administrations"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_1_for_report_7"/>
        <NamedIndividual IRI="#one_day_interval_between_administrations"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_interval_between_administrations"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_1_for_report_9"/>
        <NamedIndividual IRI="#one_day_interval_between_administrations"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_interval_between_administrations"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_2_for_report_7"/>
        <NamedIndividual IRI="#one_day_interval_between_administrations"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_interval_between_administrations"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_2_for_report_9"/>
        <NamedIndividual IRI="#one_day_interval_between_administrations"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_interval_between_administrations"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_3_for_report_7"/>
        <NamedIndividual IRI="#one_day_interval_between_administrations"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_interval_between_administrations"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_4_for_report_7"/>
        <NamedIndividual IRI="#one_day_interval_between_administrations"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_interval_between_administrations"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_5_for_report_7"/>
        <NamedIndividual IRI="#one_day_interval_between_administrations"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_interval_between_administrations"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_for_report_11"/>
        <NamedIndividual IRI="#one_day_interval_between_administrations"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_interval_between_administrations"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_for_report_12"/>
        <NamedIndividual IRI="#one_day_interval_between_administrations"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_drug"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_for_report_2"/>
        <NamedIndividual IRI="#Ibrutinib"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_interval_between_administrations"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_for_report_2"/>
        <NamedIndividual IRI="#one_day_interval_between_administrations"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_drug"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_for_report_3"/>
        <NamedIndividual IRI="#Ibrutinib"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_interval_between_administrations"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_for_report_3"/>
        <NamedIndividual IRI="#one_day_interval_between_administrations"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_drug"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_for_report_4"/>
        <NamedIndividual IRI="#Ibrutinib"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_interval_between_administrations"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_for_report_4"/>
        <NamedIndividual IRI="#one_day_interval_between_administrations"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_drug"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_for_report_5"/>
        <NamedIndividual IRI="#Ibrutinib"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_interval_between_administrations"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_for_report_5"/>
        <NamedIndividual IRI="#one_day_interval_between_administrations"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:concerns_indication_for_use"/>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_10"/>
        <NamedIndividual IRI="#mantle_cell_lymphoma_(MCL)"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_drug"/>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_10"/>
        <NamedIndividual IRI="#Ibrutinib"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:concerns_indication_for_use"/>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_11"/>
        <NamedIndividual IRI="#chronic_lymphatic_leukaemia_(CLL)"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_dosage"/>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_11"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_for_report_11"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_drug"/>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_11"/>
        <NamedIndividual IRI="#Ibrutinib"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:concerns_indication_for_use"/>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_12"/>
        <NamedIndividual IRI="#chronic_lymphatic_leukaemia_(CLL)"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:concerns_indication_for_use"/>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_12"/>
        <NamedIndividual IRI="#mantle_cell_lymphoma_(MCL)"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_dosage"/>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_12"/>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_12"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_drug"/>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_12"/>
        <NamedIndividual IRI="#Ibrutinib"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:concerns_indication_for_use"/>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_2"/>
        <NamedIndividual IRI="#chronic_lymphatic_leukaemia_(CLL)"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_dosage"/>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_2"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_for_report_2"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:concerns_indication_for_use"/>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_3"/>
        <NamedIndividual IRI="#mantle_cell_lymphoma_(MCL)"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_dosage"/>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_3"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_for_report_3"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:concerns_indication_for_use"/>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_4"/>
        <NamedIndividual IRI="#Follicular_lymphoma"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_dosage"/>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_4"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_for_report_4"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:concerns_indication_for_use"/>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_5"/>
        <NamedIndividual IRI="#chronic_lymphatic_leukaemia_(CLL)"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_dosage"/>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_5"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_for_report_5"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:concerns_indication_for_use"/>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_7"/>
        <NamedIndividual IRI="#chronic_lymphatic_leukaemia_(CLL)"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_dosage"/>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_7"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_1_for_report_7"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_dosage"/>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_7"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_2_for_report_7"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_dosage"/>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_7"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_3_for_report_7"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_dosage"/>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_7"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_4_for_report_7"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_dosage"/>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_7"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_5_for_report_7"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_drug"/>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_7"/>
        <NamedIndividual IRI="#Ibrutinib"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:concerns_indication_for_use"/>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_8"/>
        <NamedIndividual IRI="#chronic_lymphatic_leukaemia_(CLL)"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_drug"/>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_8"/>
        <NamedIndividual IRI="#Ibrutinib"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:concerns_indication_for_use"/>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_9"/>
        <NamedIndividual IRI="#chronic_lymphatic_leukaemia_(CLL)"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_dosage"/>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_9"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_1_for_report_9"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_dosage"/>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_9"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_2_for_report_9"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_drug"/>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_9"/>
        <NamedIndividual IRI="#Ibrutinib"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="mp:references"/>
        <NamedIndividual IRI="#Introduction"/>
        <NamedIndividual IRI="#1._European_Medicines_Agency:_Summary_of_Product_Characteristics_for_ibrutinib_(Imbruvica®)._Available_from:_http://www.ema.europa.eu/docs/en_GB/_document_library/EPAR_-_Product_Information/_human/003791/WC500177775.pdf._Accessed:_September_2016."/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="mp:references"/>
        <NamedIndividual IRI="#Literature_and_Labelling"/>
        <NamedIndividual IRI="#7._Mato_AR,_Islam_P,_Daniel_C,_Strelec_L,_Kaye_AH,_Brooks_S,_et_al._Ibrutinib-induced_pneumonitis_in_patients_with_chronic_lymphocytic_leukemia._Blood,_2016._Feb_25;127(8):1064-7."/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="mp:references"/>
        <NamedIndividual IRI="#Literature_and_Labelling"/>
        <NamedIndividual IRI="#8._Shah_RR._Tyrosine_Kinase_Inhibitor-Induced_Interstitial_Lung_Disease:_Clinical_Features,_Diagnostic_Challenges,_and_Therapeutic_Dilemmas._Drug_Saf._2016_Aug_17._[Epub_ahead_of_print]."/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_part_of"/>
        <NamedIndividual IRI="#Mato_cases_description"/>
        <NamedIndividual IRI="#Literature_and_Labelling"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:concerns_indication_for_use"/>
        <NamedIndividual IRI="#Report_1"/>
        <NamedIndividual IRI="#chronic_lymphatic_leukaemia_(CLL)"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_related_with_concomitant_drug"/>
        <NamedIndividual IRI="#Report_1"/>
        <NamedIndividual IRI="#Insulin"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_related_with_concomitant_drug"/>
        <NamedIndividual IRI="#Report_1"/>
        <NamedIndividual IRI="#Valaciclovir"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_related_with_primary_suspect_drug"/>
        <NamedIndividual IRI="#Report_1"/>
        <NamedIndividual IRI="#Ibrutinib"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_adverse_effect"/>
        <NamedIndividual IRI="#Report_1"/>
        <NamedIndividual IRI="#Pneumonitis"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_patient"/>
        <NamedIndividual IRI="#Report_1"/>
        <NamedIndividual IRI="#Patient_1"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:time_to_onset"/>
        <NamedIndividual IRI="#Report_1"/>
        <NamedIndividual IRI="#onset_time_for_report_1"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_related_with_concomitant_drug"/>
        <NamedIndividual IRI="#Report_10"/>
        <NamedIndividual IRI="#Filgrastim"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_related_with_primary_suspect_drug"/>
        <NamedIndividual IRI="#Report_10"/>
        <NamedIndividual IRI="#Ibrutinib"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_adverse_effect"/>
        <NamedIndividual IRI="#Report_10"/>
        <NamedIndividual IRI="#Pneumonitis"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_patient"/>
        <NamedIndividual IRI="#Report_10"/>
        <NamedIndividual IRI="#Patient_10"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_reported_drug_usage"/>
        <NamedIndividual IRI="#Report_10"/>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_10"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:time_to_onset"/>
        <NamedIndividual IRI="#Report_10"/>
        <NamedIndividual IRI="#onset_time_for_report_10"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_related_with_primary_suspect_drug"/>
        <NamedIndividual IRI="#Report_11"/>
        <NamedIndividual IRI="#Ibrutinib"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_adverse_effect"/>
        <NamedIndividual IRI="#Report_11"/>
        <NamedIndividual IRI="#Pneumonitis"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_adverse_effect"/>
        <NamedIndividual IRI="#Report_11"/>
        <NamedIndividual IRI="#Sodium_decreased"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_patient"/>
        <NamedIndividual IRI="#Report_11"/>
        <NamedIndividual IRI="#Patient_11"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_reported_drug_usage"/>
        <NamedIndividual IRI="#Report_11"/>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_11"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:time_to_onset"/>
        <NamedIndividual IRI="#Report_11"/>
        <NamedIndividual IRI="#onset_time_for_report_11"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_related_with_concomitant_drug"/>
        <NamedIndividual IRI="#Report_12"/>
        <NamedIndividual IRI="#Aminophylline"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_related_with_concomitant_drug"/>
        <NamedIndividual IRI="#Report_12"/>
        <NamedIndividual IRI="#Amlodipine"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_related_with_concomitant_drug"/>
        <NamedIndividual IRI="#Report_12"/>
        <NamedIndividual IRI="#Enoxaparin"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_related_with_concomitant_drug"/>
        <NamedIndividual IRI="#Report_12"/>
        <NamedIndividual IRI="#Pantoprazole"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_related_with_concomitant_drug"/>
        <NamedIndividual IRI="#Report_12"/>
        <NamedIndividual IRI="#Tamsulosin"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_related_with_primary_suspect_drug"/>
        <NamedIndividual IRI="#Report_12"/>
        <NamedIndividual IRI="#Ibrutinib"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_adverse_effect"/>
        <NamedIndividual IRI="#Report_12"/>
        <NamedIndividual IRI="#Pneumonia"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_adverse_effect"/>
        <NamedIndividual IRI="#Report_12"/>
        <NamedIndividual IRI="#Pneumonitis"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_patient"/>
        <NamedIndividual IRI="#Report_12"/>
        <NamedIndividual IRI="#Patient_12"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_reported_drug_usage"/>
        <NamedIndividual IRI="#Report_12"/>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_12"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:time_to_onset"/>
        <NamedIndividual IRI="#Report_12"/>
        <NamedIndividual IRI="#onset_time_for_report_12"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_related_with_primary_suspect_drug"/>
        <NamedIndividual IRI="#Report_2"/>
        <NamedIndividual IRI="#Ibrutinib"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_related_with_secondary_suspect_drug"/>
        <NamedIndividual IRI="#Report_2"/>
        <NamedIndividual IRI="#Rituximab"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_adverse_effect"/>
        <NamedIndividual IRI="#Report_2"/>
        <NamedIndividual IRI="#Acute_kidney_injure"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_adverse_effect"/>
        <NamedIndividual IRI="#Report_2"/>
        <NamedIndividual IRI="#Anemia"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_adverse_effect"/>
        <NamedIndividual IRI="#Report_2"/>
        <NamedIndividual IRI="#Diarrhea"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_adverse_effect"/>
        <NamedIndividual IRI="#Report_2"/>
        <NamedIndividual IRI="#Pneumonitis"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_adverse_effect"/>
        <NamedIndividual IRI="#Report_2"/>
        <NamedIndividual IRI="#Pyrexia"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_patient"/>
        <NamedIndividual IRI="#Report_2"/>
        <NamedIndividual IRI="#Patient_2"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_reported_drug_usage"/>
        <NamedIndividual IRI="#Report_2"/>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_2"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:time_to_onset"/>
        <NamedIndividual IRI="#Report_2"/>
        <NamedIndividual IRI="#onset_time_for_report_2"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_related_with_concomitant_drug"/>
        <NamedIndividual IRI="#Report_3"/>
        <NamedIndividual IRI="#Acetylsalicylic_Acid"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_related_with_concomitant_drug"/>
        <NamedIndividual IRI="#Report_3"/>
        <NamedIndividual IRI="#Amlodipine"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_related_with_concomitant_drug"/>
        <NamedIndividual IRI="#Report_3"/>
        <NamedIndividual IRI="#Ezetimibe"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_related_with_concomitant_drug"/>
        <NamedIndividual IRI="#Report_3"/>
        <NamedIndividual IRI="#Levothyroxine"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_related_with_concomitant_drug"/>
        <NamedIndividual IRI="#Report_3"/>
        <NamedIndividual IRI="#Metoprolol"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_related_with_concomitant_drug"/>
        <NamedIndividual IRI="#Report_3"/>
        <NamedIndividual IRI="#Pantoprazole"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_related_with_concomitant_drug"/>
        <NamedIndividual IRI="#Report_3"/>
        <NamedIndividual IRI="#Rosuvastatin"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_related_with_concomitant_drug"/>
        <NamedIndividual IRI="#Report_3"/>
        <NamedIndividual IRI="#Ω-3-acid"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_related_with_primary_suspect_drug"/>
        <NamedIndividual IRI="#Report_3"/>
        <NamedIndividual IRI="#Ibrutinib"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_patient"/>
        <NamedIndividual IRI="#Report_3"/>
        <NamedIndividual IRI="#Patient_3"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_reported_drug_usage"/>
        <NamedIndividual IRI="#Report_3"/>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_3"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:time_to_onset"/>
        <NamedIndividual IRI="#Report_3"/>
        <NamedIndividual IRI="#onset_time_for_report_3"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_related_with_primary_suspect_drug"/>
        <NamedIndividual IRI="#Report_4"/>
        <NamedIndividual IRI="#Ibrutinib"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_related_with_secondary_suspect_drug"/>
        <NamedIndividual IRI="#Report_4"/>
        <NamedIndividual IRI="#Bendamustine"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_related_with_secondary_suspect_drug"/>
        <NamedIndividual IRI="#Report_4"/>
        <NamedIndividual IRI="#Rituximab"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_adverse_effect"/>
        <NamedIndividual IRI="#Report_4"/>
        <NamedIndividual IRI="#Acute_Respiratory_Distress_Syndrome"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_adverse_effect"/>
        <NamedIndividual IRI="#Report_4"/>
        <NamedIndividual IRI="#Pneumonitis"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_adverse_effect"/>
        <NamedIndividual IRI="#Report_4"/>
        <NamedIndividual IRI="#Rhinovirus_infection"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_reported_drug_usage"/>
        <NamedIndividual IRI="#Report_4"/>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_4"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:time_to_onset"/>
        <NamedIndividual IRI="#Report_4"/>
        <NamedIndividual IRI="#onset_time_for_report_4"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_related_with_concomitant_drug"/>
        <NamedIndividual IRI="#Report_5"/>
        <NamedIndividual IRI="#Metformin"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_related_with_concomitant_drug"/>
        <NamedIndividual IRI="#Report_5"/>
        <NamedIndividual IRI="#Nifedipine"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_related_with_concomitant_drug"/>
        <NamedIndividual IRI="#Report_5"/>
        <NamedIndividual IRI="#Oxycodone"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_related_with_concomitant_drug"/>
        <NamedIndividual IRI="#Report_5"/>
        <NamedIndividual IRI="#Pioglitazone"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_related_with_concomitant_drug"/>
        <NamedIndividual IRI="#Report_5"/>
        <NamedIndividual IRI="#Warfarin"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_related_with_primary_suspect_drug"/>
        <NamedIndividual IRI="#Report_5"/>
        <NamedIndividual IRI="#Ibrutinib"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_adverse_effect"/>
        <NamedIndividual IRI="#Report_5"/>
        <NamedIndividual IRI="#Atrial_Fibrillation"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_adverse_effect"/>
        <NamedIndividual IRI="#Report_5"/>
        <NamedIndividual IRI="#Congestive_cardiac_failure"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_adverse_effect"/>
        <NamedIndividual IRI="#Report_5"/>
        <NamedIndividual IRI="#Pneumonitis"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_adverse_effect"/>
        <NamedIndividual IRI="#Report_5"/>
        <NamedIndividual IRI="#Swelling"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_patient"/>
        <NamedIndividual IRI="#Report_5"/>
        <NamedIndividual IRI="#Patient_5"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_reported_drug_usage"/>
        <NamedIndividual IRI="#Report_5"/>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_5"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:time_to_onset"/>
        <NamedIndividual IRI="#Report_5"/>
        <NamedIndividual IRI="#onset_time_for_report_5"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:concerns_indication_for_use"/>
        <NamedIndividual IRI="#Report_6"/>
        <NamedIndividual IRI="#chronic_lymphatic_leukaemia_(CLL)"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_related_with_primary_suspect_drug"/>
        <NamedIndividual IRI="#Report_6"/>
        <NamedIndividual IRI="#Ibrutinib"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_adverse_effect"/>
        <NamedIndividual IRI="#Report_6"/>
        <NamedIndividual IRI="#Pneumonitis"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_adverse_effect"/>
        <NamedIndividual IRI="#Report_6"/>
        <NamedIndividual IRI="#Sepsis"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_patient"/>
        <NamedIndividual IRI="#Report_6"/>
        <NamedIndividual IRI="#Patient_6"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_related_with_primary_suspect_drug"/>
        <NamedIndividual IRI="#Report_7"/>
        <NamedIndividual IRI="#Ibrutinib"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_adverse_effect"/>
        <NamedIndividual IRI="#Report_7"/>
        <NamedIndividual IRI="#Arthralgia"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_adverse_effect"/>
        <NamedIndividual IRI="#Report_7"/>
        <NamedIndividual IRI="#Bone_pain"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_adverse_effect"/>
        <NamedIndividual IRI="#Report_7"/>
        <NamedIndividual IRI="#Cough"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_adverse_effect"/>
        <NamedIndividual IRI="#Report_7"/>
        <NamedIndividual IRI="#Fatigue"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_adverse_effect"/>
        <NamedIndividual IRI="#Report_7"/>
        <NamedIndividual IRI="#Muscle_spasms"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_adverse_effect"/>
        <NamedIndividual IRI="#Report_7"/>
        <NamedIndividual IRI="#Myalgia"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_adverse_effect"/>
        <NamedIndividual IRI="#Report_7"/>
        <NamedIndividual IRI="#Nasopharyngitis"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_adverse_effect"/>
        <NamedIndividual IRI="#Report_7"/>
        <NamedIndividual IRI="#Nausea"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_adverse_effect"/>
        <NamedIndividual IRI="#Report_7"/>
        <NamedIndividual IRI="#Peripheral_swelling"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_adverse_effect"/>
        <NamedIndividual IRI="#Report_7"/>
        <NamedIndividual IRI="#Pneumonitis"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_adverse_effect"/>
        <NamedIndividual IRI="#Report_7"/>
        <NamedIndividual IRI="#Pulmonary_fibrosis"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_adverse_effect"/>
        <NamedIndividual IRI="#Report_7"/>
        <NamedIndividual IRI="#Pyrexia"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_patient"/>
        <NamedIndividual IRI="#Report_7"/>
        <NamedIndividual IRI="#Patient_7"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_reported_drug_usage"/>
        <NamedIndividual IRI="#Report_7"/>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_7"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:time_to_onset"/>
        <NamedIndividual IRI="#Report_7"/>
        <NamedIndividual IRI="#onset_time_for_report_7"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_related_with_primary_suspect_drug"/>
        <NamedIndividual IRI="#Report_8"/>
        <NamedIndividual IRI="#Ibrutinib"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_adverse_effect"/>
        <NamedIndividual IRI="#Report_8"/>
        <NamedIndividual IRI="#Pneumonitis"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_adverse_effect"/>
        <NamedIndividual IRI="#Report_8"/>
        <NamedIndividual IRI="#Respiratory_failure"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_patient"/>
        <NamedIndividual IRI="#Report_8"/>
        <NamedIndividual IRI="#Patient_8"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_reported_drug_usage"/>
        <NamedIndividual IRI="#Report_8"/>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_8"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_related_with_primary_suspect_drug"/>
        <NamedIndividual IRI="#Report_9"/>
        <NamedIndividual IRI="#Ibrutinib"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_adverse_effect"/>
        <NamedIndividual IRI="#Report_9"/>
        <NamedIndividual IRI="#Pneumonitis"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_patient"/>
        <NamedIndividual IRI="#Report_9"/>
        <NamedIndividual IRI="#Patient_9"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_reported_drug_usage"/>
        <NamedIndividual IRI="#Report_9"/>
        <NamedIndividual IRI="#Ibrutinib_usage_for_report_9"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:time_to_onset"/>
        <NamedIndividual IRI="#Report_9"/>
        <NamedIndividual IRI="#onset_time_for_report_9"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="mp:references"/>
        <NamedIndividual IRI="#Reports_in_VigiBase"/>
        <NamedIndividual IRI="#1._European_Medicines_Agency:_Summary_of_Product_Characteristics_for_ibrutinib_(Imbruvica®)._Available_from:_http://www.ema.europa.eu/docs/en_GB/_document_library/EPAR_-_Product_Information/_human/003791/WC500177775.pdf._Accessed:_September_2016."/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="mp:references"/>
        <NamedIndividual IRI="#Reports_in_VigiBase"/>
        <NamedIndividual IRI="#2._European_Medicines_Agency:_Summary_of_Product_Characteristics_for_rituximab_(MabThera®)._Available_from:_http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000165/WC500025821.pdf._Accessed:_October_2016."/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="mp:references"/>
        <NamedIndividual IRI="#Reports_in_VigiBase"/>
        <NamedIndividual IRI="#3._European_Medicines_Agency:_Summary_of_Product_Characteristics_for_everolimus_(Afinitor®)._Available_from:_http://www.ema.europa.eu/docs/en_GB/_document_library/EPAR_-_Product_Information/_human/001038/WC500022814.pdf._Accessed:_October_2016."/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="mp:references"/>
        <NamedIndividual IRI="#Reports_in_VigiBase"/>
        <NamedIndividual IRI="#4._US_Food_and_Drug_Administration:_Product_label_for_bendamustine_(Treanda®)._Available_from:_http://www.accessdata.fda.gov/drugsatfda__docs/label/2016/022249s022lbl.pdf._Accessed:_October_2016."/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="mp:references"/>
        <NamedIndividual IRI="#Reports_in_VigiBase"/>
        <NamedIndividual IRI="#5._Electronic_Medicines_Compendium:_Summary_of_Product_Characteristics_for_mesalazine_(Asacol®)._Available_from:_https://www.medicines.org.uk/emc/_medicine/20478._Accessed:_October_2016."/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="mp:references"/>
        <NamedIndividual IRI="#Reports_in_VigiBase"/>
        <NamedIndividual IRI="#6._Electronic_Medicines_Compendium:_Summary_of_Product_Characteristics_for_filgrastim_(Neupogen®)._Available_from:_https://www.medicines.org.uk/emc/_medicine/27485._Accessed:_October_2016."/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_part_of"/>
        <NamedIndividual IRI="#ibrutinib_ADR_mechanism"/>
        <NamedIndividual IRI="#Literature_and_Labelling"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="mp:references"/>
        <NamedIndividual IRI="#ibrutinib_ADR_mechanism"/>
        <NamedIndividual IRI="#7._Mato_AR,_Islam_P,_Daniel_C,_Strelec_L,_Kaye_AH,_Brooks_S,_et_al._Ibrutinib-induced_pneumonitis_in_patients_with_chronic_lymphocytic_leukemia._Blood,_2016._Feb_25;127(8):1064-7."/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_part_of"/>
        <NamedIndividual IRI="#ibrutinib_mechanism"/>
        <NamedIndividual IRI="#Introduction"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="mp:references"/>
        <NamedIndividual IRI="#ibrutinib_mechanism"/>
        <NamedIndividual IRI="#1._European_Medicines_Agency:_Summary_of_Product_Characteristics_for_ibrutinib_(Imbruvica®)._Available_from:_http://www.ema.europa.eu/docs/en_GB/_document_library/EPAR_-_Product_Information/_human/003791/WC500177775.pdf._Accessed:_September_2016."/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_part_of"/>
        <NamedIndividual IRI="#ibrutinib_metabolism"/>
        <NamedIndividual IRI="#Literature_and_Labelling"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_adverse_effect"/>
        <NamedIndividual IRI="#ibrutinib_metabolism"/>
        <NamedIndividual IRI="#Toxicity"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_drug"/>
        <NamedIndividual IRI="#ibrutinib_metabolism"/>
        <NamedIndividual IRI="#Ibrutinib"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_adverse_effect"/>
        <NamedIndividual IRI="#pkis_and_cardiotoxicity"/>
        <NamedIndividual IRI="#Cardiotoxicity"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_class"/>
        <NamedIndividual IRI="#pkis_and_cardiotoxicity"/>
        <NamedIndividual IRI="#protein_kinase_inhibitors"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="mp:references"/>
        <NamedIndividual IRI="#pkis_and_cardiotoxicity"/>
        <NamedIndividual IRI="#Literature_and_Labelling"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_adverse_effect"/>
        <NamedIndividual IRI="#pkis_and_electrolytes"/>
        <NamedIndividual IRI="#Electrolyte_disturbances"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_class"/>
        <NamedIndividual IRI="#pkis_and_electrolytes"/>
        <NamedIndividual IRI="#protein_kinase_inhibitors"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="mp:references"/>
        <NamedIndividual IRI="#pkis_and_electrolytes"/>
        <NamedIndividual IRI="#Literature_and_Labelling"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_adverse_effect"/>
        <NamedIndividual IRI="#pkis_and_hepatotoxicity"/>
        <NamedIndividual IRI="#Hepatotoxicity"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_class"/>
        <NamedIndividual IRI="#pkis_and_hepatotoxicity"/>
        <NamedIndividual IRI="#protein_kinase_inhibitors"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="mp:references"/>
        <NamedIndividual IRI="#pkis_and_hepatotoxicity"/>
        <NamedIndividual IRI="#Literature_and_Labelling"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_adverse_effect"/>
        <NamedIndividual IRI="#pkis_and_hypertension"/>
        <NamedIndividual IRI="#Hypertension"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_class"/>
        <NamedIndividual IRI="#pkis_and_hypertension"/>
        <NamedIndividual IRI="#protein_kinase_inhibitors"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="mp:references"/>
        <NamedIndividual IRI="#pkis_and_hypertension"/>
        <NamedIndividual IRI="#Literature_and_Labelling"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_adverse_effect"/>
        <NamedIndividual IRI="#pkis_and_pneumonia"/>
        <NamedIndividual IRI="#Pneumonia"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_class"/>
        <NamedIndividual IRI="#pkis_and_pneumonia"/>
        <NamedIndividual IRI="#protein_kinase_inhibitors"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="mp:referencedBy"/>
        <NamedIndividual IRI="#pkis_and_pneumonia"/>
        <NamedIndividual IRI="#Literature_and_Labelling"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_adverse_effect"/>
        <NamedIndividual IRI="#pkis_and_pneumonitis"/>
        <NamedIndividual IRI="#Pneumonitis"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_class"/>
        <NamedIndividual IRI="#pkis_and_pneumonitis"/>
        <NamedIndividual IRI="#protein_kinase_inhibitors"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="mp:references"/>
        <NamedIndividual IRI="#pkis_and_pneumonitis"/>
        <NamedIndividual IRI="#Summary"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_subgroup_of"/>
        <NamedIndividual IRI="#reports_dechallenged_having_recovery_as_outcome"/>
        <NamedIndividual IRI="#Overall_reports_in_Vigibase"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_subgroup_of"/>
        <NamedIndividual IRI="#reports_from_Germany"/>
        <NamedIndividual IRI="#Overall_reports_in_Vigibase"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty IRI="http://www.w3.org/ns/prov#atLocation"/>
        <NamedIndividual IRI="#reports_from_Germany"/>
        <NamedIndividual IRI="#Germany"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_subgroup_of"/>
        <NamedIndividual IRI="#reports_from_Italy"/>
        <NamedIndividual IRI="#Overall_reports_in_Vigibase"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty IRI="http://www.w3.org/ns/prov#atLocation"/>
        <NamedIndividual IRI="#reports_from_Italy"/>
        <NamedIndividual IRI="#Italy"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_subgroup_of"/>
        <NamedIndividual IRI="#reports_from_UK"/>
        <NamedIndividual IRI="#Overall_reports_in_Vigibase"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty IRI="http://www.w3.org/ns/prov#atLocation"/>
        <NamedIndividual IRI="#reports_from_UK"/>
        <NamedIndividual IRI="#United_Kingdom"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_subgroup_of"/>
        <NamedIndividual IRI="#reports_from_USA"/>
        <NamedIndividual IRI="#Overall_reports_in_Vigibase"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty IRI="http://www.w3.org/ns/prov#atLocation"/>
        <NamedIndividual IRI="#reports_from_USA"/>
        <NamedIndividual IRI="#USA"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:concerns_indication_for_use"/>
        <NamedIndividual IRI="#reports_having_CLL_as_indication"/>
        <NamedIndividual IRI="#chronic_lymphatic_leukaemia_(CLL)"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_subgroup_of"/>
        <NamedIndividual IRI="#reports_having_CLL_as_indication"/>
        <NamedIndividual IRI="#Overall_reports_in_Vigibase"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:concerns_indication_for_use"/>
        <NamedIndividual IRI="#reports_having_MCL_as_indication"/>
        <NamedIndividual IRI="#mantle_cell_lymphoma_(MCL)"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_subgroup_of"/>
        <NamedIndividual IRI="#reports_having_MCL_as_indication"/>
        <NamedIndividual IRI="#Overall_reports_in_Vigibase"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_subgroup_of"/>
        <NamedIndividual IRI="#reports_having_fatal_outcome"/>
        <NamedIndividual IRI="#Overall_reports_in_Vigibase"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_related_with_primary_suspect_drug"/>
        <NamedIndividual IRI="#reports_having_ibrutinib_as_primary_suspect_drug"/>
        <NamedIndividual IRI="#Ibrutinib"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_subgroup_of"/>
        <NamedIndividual IRI="#reports_having_ibrutinib_as_primary_suspect_drug"/>
        <NamedIndividual IRI="#Overall_reports_in_Vigibase"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_subgroup_of"/>
        <NamedIndividual IRI="#reports_with_negative_rechallenge"/>
        <NamedIndividual IRI="#Overall_reports_in_Vigibase"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_supported_by_spontaneous_report"/>
        <NamedIndividual IRI="#signal_in_the_report"/>
        <NamedIndividual IRI="#Report_1"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_supported_by_spontaneous_report"/>
        <NamedIndividual IRI="#signal_in_the_report"/>
        <NamedIndividual IRI="#Report_10"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_supported_by_spontaneous_report"/>
        <NamedIndividual IRI="#signal_in_the_report"/>
        <NamedIndividual IRI="#Report_11"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_supported_by_spontaneous_report"/>
        <NamedIndividual IRI="#signal_in_the_report"/>
        <NamedIndividual IRI="#Report_12"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_supported_by_spontaneous_report"/>
        <NamedIndividual IRI="#signal_in_the_report"/>
        <NamedIndividual IRI="#Report_2"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_supported_by_spontaneous_report"/>
        <NamedIndividual IRI="#signal_in_the_report"/>
        <NamedIndividual IRI="#Report_3"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_supported_by_spontaneous_report"/>
        <NamedIndividual IRI="#signal_in_the_report"/>
        <NamedIndividual IRI="#Report_4"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_supported_by_spontaneous_report"/>
        <NamedIndividual IRI="#signal_in_the_report"/>
        <NamedIndividual IRI="#Report_5"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_supported_by_spontaneous_report"/>
        <NamedIndividual IRI="#signal_in_the_report"/>
        <NamedIndividual IRI="#Report_6"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_supported_by_spontaneous_report"/>
        <NamedIndividual IRI="#signal_in_the_report"/>
        <NamedIndividual IRI="#Report_7"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_supported_by_spontaneous_report"/>
        <NamedIndividual IRI="#signal_in_the_report"/>
        <NamedIndividual IRI="#Report_8"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_supported_by_spontaneous_report"/>
        <NamedIndividual IRI="#signal_in_the_report"/>
        <NamedIndividual IRI="#Report_9"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_supported_by_spontaneous_report"/>
        <NamedIndividual IRI="#signal_in_the_report"/>
        <NamedIndividual IRI="#reports_from_Italy"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_supported_by_statistical_entity"/>
        <NamedIndividual IRI="#signal_in_the_report"/>
        <NamedIndividual IRI="#Overall_reports_in_Vigibase"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_supported_by_statistical_entity"/>
        <NamedIndividual IRI="#signal_in_the_report"/>
        <NamedIndividual IRI="#reports_dechallenged_having_recovery_as_outcome"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_supported_by_statistical_entity"/>
        <NamedIndividual IRI="#signal_in_the_report"/>
        <NamedIndividual IRI="#reports_from_Germany"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_supported_by_statistical_entity"/>
        <NamedIndividual IRI="#signal_in_the_report"/>
        <NamedIndividual IRI="#reports_from_UK"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_supported_by_statistical_entity"/>
        <NamedIndividual IRI="#signal_in_the_report"/>
        <NamedIndividual IRI="#reports_from_USA"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_supported_by_statistical_entity"/>
        <NamedIndividual IRI="#signal_in_the_report"/>
        <NamedIndividual IRI="#reports_having_CLL_as_indication"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_supported_by_statistical_entity"/>
        <NamedIndividual IRI="#signal_in_the_report"/>
        <NamedIndividual IRI="#reports_having_MCL_as_indication"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_supported_by_statistical_entity"/>
        <NamedIndividual IRI="#signal_in_the_report"/>
        <NamedIndividual IRI="#reports_having_fatal_outcome"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_supported_by_statistical_entity"/>
        <NamedIndividual IRI="#signal_in_the_report"/>
        <NamedIndividual IRI="#reports_having_ibrutinib_as_primary_suspect_drug"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:is_supported_by_statistical_entity"/>
        <NamedIndividual IRI="#signal_in_the_report"/>
        <NamedIndividual IRI="#reports_with_negative_rechallenge"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_adverse_effect"/>
        <NamedIndividual IRI="#signal_in_the_report"/>
        <NamedIndividual IRI="#Pneumonitis"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="open-pv:refers_to_drug"/>
        <NamedIndividual IRI="#signal_in_the_report"/>
        <NamedIndividual IRI="#Ibrutinib"/>
    </ObjectPropertyAssertion>
    <ObjectPropertyAssertion>
        <ObjectProperty abbreviatedIRI="oa#:hasSelector"/>
        <AnonymousIndividual nodeID="_:genid13788"/>
        <NamedIndividual IRI="#Selector_1"/>
    </ObjectPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_content"/>
        <NamedIndividual IRI="#Discussion_and_Conclusion"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">There are 21 PKIs for which pneumonitis has been disproportionately reported in VigiBase. The vast majority of them have pneumonitis, or less often, ILD present in their labelling. Ibrutinib, with 39 reports on pneumonitis and 7 on ILD in VigiBase is one of the few exceptions to this. 
The 39 cases of pneumonitis reported show a reasonably consistent pattern and history to support a causal relationship between ibrutinib and pneumonitis. The temporal association in the majority of cases supports a causal relationship being similar to the natural history of pneumonitis.
The majority of cases were reported by the physician diagnosing and treating the event, but the level of detail in the description of diagnostic methods used is not high. A positive dechallenge and outcome is described in many of the cases, in some also recording steroid treatment. Antibiotic treatment is often mentioned which would be expected considering that when diagnosing pneumonitis symptoms of respiratory infections overlap with those of pneumonitis and serious infectious processes always have to be ruled out and treated. No case of certain positive rechallenge is described in the spontaneously reported cases.
In some cases there are other explanations or evident confounders present; other suspected or concomitant drugs; in some cases, several previous lines of treatment for the disease, and in at least one case prior radiotherapy to the chest could be possible predisposing factors of the pneumonitis. The underlying disease may have contributed in only few of the cases reported. Likewise, few of the reported cases describe previous potentially predisposing respiratory disease; one patient did have a history of recurrent pneumonitis. In four of the cases a negative rechallenge at the same or lower dose is described. The reports from Italy pose a specific challenge in that due to translation and nomenclature issues we cannot rule out the possibility that among them may be cases of pneumonia rather than pneumonitis.
The publication by Mato et al. on four further thoroughly evaluated and described cases with similar histories strongly supports the signal. 
In summary, with a clinical suspicion and a pattern in a majority of reported cases consistent with drug induced pneumonitis and a recent publication describing a series of clinically detailed described cases with a strong suspicion of causality, with the vast majority of
drugs in the protein kinase inhibiting class having pneumonitis or interstitial lung disease as an acknowledged side effect in their labelling; the signal of pneumonitis induced by ibrutinib merits further investigation to assess the need for possible risk minimising activities by relevant stakeholders.</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_subject"/>
        <NamedIndividual IRI="#Discussion_and_Conclusion"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">Discussion and Conclusion</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_affiliation"/>
        <NamedIndividual IRI="#Dr_Birgitta_Grundmark"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">Uppsala Monitoring Centre</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_first_name"/>
        <NamedIndividual IRI="#Dr_Birgitta_Grundmark"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">Birgitta</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_last_name"/>
        <NamedIndividual IRI="#Dr_Birgitta_Grundmark"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">Grundmark</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_content"/>
        <NamedIndividual IRI="#Editorial_Comment"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">Since the finalization of the evaluation of the signal pneumonitis in relation to ibrutinib, the closely related term “interstitial lung disease” (ILD) has been included into the EU SmPC as an acknowledged side effect; hence the signal detected by the UMC has been confirmed by regulatory bodies and the MAH. Advice on appropriate monitoring of patients regarding ILD and on the clinical handling of patients in whom ILD has occurred has also been added.</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_subject"/>
        <NamedIndividual IRI="#Editorial_Comment"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">Editorial Comment</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_creation_date"/>
        <NamedIndividual IRI="#Ibrutinib_and_pneumonitis_UMC_WHO_report"/>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#date">2017-07-01</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_overall_conclusion"/>
        <NamedIndividual IRI="#Ibrutinib_and_pneumonitis_UMC_WHO_report"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">causal association probable</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:refers_to_dosage_value"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_1_for_report_7"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">420mg</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:refers_to_dosage_value"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_1_for_report_9"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">420mg</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:refers_to_dosage_value"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_2_for_report_7"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">560mg</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:refers_to_dosage_value"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_2_for_report_9"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">280mg</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:refers_to_rechallenge_process"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_2_for_report_9"/>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#boolean">true</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:refers_to_dechallenge_process"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_3_for_report_7"/>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#boolean">true</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:refers_to_dosage_value"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_3_for_report_7"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">280mg</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:refers_to_dosage_value"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_4_for_report_7"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">420mg</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:refers_to_rechallenge_process"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_4_for_report_7"/>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#boolean">true</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:refers_to_dechallenge_process"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_5_for_report_7"/>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#boolean">true</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:refers_to_dosage_value"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_5_for_report_7"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">280mg</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:refers_to_dosage_value"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_for_report_11"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">420mg</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:refers_to_dosage_value"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_for_report_12"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">420mg</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:refers_to_dosage_value"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_for_report_2"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">420mg</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:refers_to_dosage_value"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_for_report_3"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">560mg</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:refers_to_dosage_value"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_for_report_4"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">560mg</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:refers_to_dosage_value"/>
        <NamedIndividual IRI="#Ibrutinib_dosage_for_report_5"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">420mg</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_content"/>
        <NamedIndividual IRI="#Introduction"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">In the regular UMC signal detection screening, the combination of ibrutinib and pneumonitis was detected in the first quarter of 2016 as a potential signal.
Ibrutinib is a small-molecule inhibitor of Bruton’s tyrosine kinase (TK). It belongs to the rapidly growing and evolving class of functionally diverse approved protein kinase inhibiting (PKI) drugs. Ibrutinib is currently the only substance with its particular mechanism of action approved for use in humans, although we understand there are others under development. Bruton’s TK is a signalling molecule within the B-cell antigen receptor (BCR) and cytokine receptor pathways necessary for B-cell trafficking, chemotaxis and adhesion. The BCR pathway is implicated in several B-cell malignancies, and ibrutinib inhibits malignant B-cell proliferation and survival. 1 The ATC code is L01XE27. Numerous approaches to target the inhibition of protein kinase (PK) signalling have been explored and developed, e.g. protein and oligonucleotide-based substances targeting growth factor or receptor TK, small-molecule inhibitors targeting unique kinase
conformational forms and binding sites. Some substances have very specific kinase selectivity profiles whereas others have a broader mode of action on several PKs.
Approvals for ibrutinib show small differences around the world and include indications in mantle cell lymphoma (MCL), chronic lymphatic leukaemia (CLL) and Waldenström’s macroglobulinaemia (WM) with a recommended dose in MCL of 560 mg daily and in CLL and WM of 420 mg daily per os. The treatment may continue until disease progression or until no longer tolerated by the patient.
Pneumonitis is an inflammation of the lung interstitium and/or alveoli. Definitions of, and borders between pneumonitis and closely related terms such as interstitial lung disease (ILD), vary somewhat between authors, languages, and medical traditions. This has become apparent while assessing this signal detected from reports from different countries. Clinically, pneumonitis is most commonly used to describe an inflammation without the presence of an infection, whereas when an infection is present it typically is classified as pneumonia. Common symptoms of pneumonitis are cough and shortness of breath alongside more general symptoms of malaise and fever. Hypoxia may or may not be present. A diagnosis of drug induced pneumonitis is usually reached based on clinical symptoms, X-ray or CT-scan, sometimes biopsy, negative cultures, and the absence and exclusion of other plausible explanations or a positive rechallenge.
Among several causes of pneumonitis are iatrogenic exposure including some antibiotics, chemotherapeutics, anti-arrhythmics and radiation treatments to the chest. Other causes include exposure to mould, bacterial or animal proteins and various chemicals and gases. Pneumonitis may also appear as a symptom of other diseases, e.g. connective tissue diseases and lymphoproliferative disorders. Treatment includes, when possible, removal of the underlying cause of the condition, systemic steroids, and if needed, oxygen and assisted respiration.
In summary, the definitions, aetiology and coding of pneumonitis and similar conditions are diverse.</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_content"/>
        <NamedIndividual IRI="#Literature_and_Labelling"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">Side effects of PKIs in general vary greatly depending on their precise mode of action with few or no side effects being common to them all. The EU SmPC states the following regarding side effects of ibrutinib:
“The safety profile is based on pooled data from 555 patients treated with IMBRUVICA in three phase 2 clinical studies and two randomised phase 3 studies and from post-marketing experience. [...] All patients in clinical studies received IMBRUVICA until disease progression or no longer tolerated. 
The most commonly occurring adverse reactions (≥ 20%) were diarrhoea, musculoskeletal pain, upper respiratory tract infection, haemorrhage, bruising, rash, and nausea. The most common grade 3/4 adverse reactions (≥ 5%) were anaemia, neutropenia, pneumonia and thrombocytopenia.”
Pneumonitis/ILD are acknowledged and labelled side effects for numerous PKIs although their detailed mode of action, molecular structure and their approved indication differ significantly and hence also their background disease and the spectrum of complications of the diseases. In VigiBase there are reports on pneumonitis/ILD for the vast majority of PKIs. There appears to be little firm knowledge on the pathophysiology of respiratory reactions in relation to PKIs in general.
Other notable side effects in several PKIs are electrolyte disturbances, hypertension, cardiotoxicity, and hepatotoxicity. Ibrutinib is primarily metabolised by cytochrome P450 enzyme 3A4 and co-administration with subsequent interaction with strong or moderate CYP3A4 inhibitors may lead to higher toxicity and is hence discouraged in the SmPC. However, no such concomitant drug or dietary use was noted in any of the reported cases.
A publication by Mato et al. recently presents four cases of ibrutinib-induced pneumonitis in patients with a diagnosis of CLL. The patients, aged between 55 and 73 years, one woman
and three men, had been diagnosed with CLL between 3 and 15 years prior to initiation of ibrutinib treatment. They had all had prior chemotherapy treatment, three of them with several courses. The time to onset of symptoms or hospitalization was between one and four months. The letter describes the authors’ extensive evaluation, including trans-bronchial biopsies and infectious workup. Examples of biopsy sections are presented. CT scans prior, during and after the events are presented and show clears signs of the condition evolving during treatment. All patients were successfully treated with steroids
and along with drug discontinuation the radiographic changes resolved, as did clinical symptoms. In one case a rechallenge was
attempted with pneumonitis reoccurring. The authors hypothesize that “inhibiting signal transduction pathways enhances expression of pro-inflammatory cytokines and the innate immune system. BTK also appears to serve as a critical mediator of lipopolysaccharide-induced dendritic cell maturation and macrophage polarization. Several studies have reported an increase in alveolar infiltration of T helper 2 pro-inflammatory cytokines in BTK-deficient mice, resulting in airway inflammation”.
A recent review by Shah on the subject of interstitial lung disease in  TKIs provides a thorough overview of the disease with a focus on the  TKIs for which this reaction is already labelled. Clinical features and laboratory findings are presented. Incidence data provided is discussed and refers to a large extent to TKIs used for non-small cell lung cancer and to Japanese patients, with their apparently different and higher susceptibility for the reaction. Onset of the reaction in TKIs based on clinical trials and post authorization studies vary heavily between different TKIs from days to many months (and usually within a year) with more severe reactions usually appearing earlier in the 
course. A discussion of the management of the reaction includes common practices for ILD namely discontinuation of the culprit, steroids, supportive care and when relevant antibiotics.</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_subject"/>
        <NamedIndividual IRI="#Literature_and_Labelling"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">Literature and Labelling</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_content"/>
        <NamedIndividual IRI="#Mato_cases_description"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">A publication by Mato et al. recently presents four cases of ibrutinib-induced pneumonitis in patients with a diagnosis of CLL. The patients, aged between 55 and 73 years, one woman and three men, had been diagnosed with CLL between 3 and 15 years prior to initiation of ibrutinib treatment. They had all had prior chemotherapy treatment, three of them with several courses. The time to onset of symptoms or hospitalization was between one and four months. The letter describes the authors’ extensive evaluation, including trans-bronchial biopsies and infectious workup. Examples of biopsy sections are presented. CT scans prior, during and after the events are presented and show clears signs of the condition evolving during treatment. All patients were successfully treated with steroids and along with drug discontinuation the radiographic changes resolved, as did clinical symptoms. In one case a rechallenge was attempted with pneumonitis reoccurring</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_average_age"/>
        <NamedIndividual IRI="#Overall_reports_in_Vigibase"/>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">69</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_count"/>
        <NamedIndividual IRI="#Overall_reports_in_Vigibase"/>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">39</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_count_of_men"/>
        <NamedIndividual IRI="#Overall_reports_in_Vigibase"/>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">27</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_count_of_women"/>
        <NamedIndividual IRI="#Overall_reports_in_Vigibase"/>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">9</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_max_age"/>
        <NamedIndividual IRI="#Overall_reports_in_Vigibase"/>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">86</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_median_age"/>
        <NamedIndividual IRI="#Overall_reports_in_Vigibase"/>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">71</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_min_age"/>
        <NamedIndividual IRI="#Overall_reports_in_Vigibase"/>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">46</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:refers_to_database"/>
        <NamedIndividual IRI="#Overall_reports_in_Vigibase"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">WHO Vigibase</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_age"/>
        <NamedIndividual IRI="#Patient_1"/>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">55</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_gender"/>
        <NamedIndividual IRI="#Patient_1"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">male</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_age"/>
        <NamedIndividual IRI="#Patient_10"/>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">69</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_gender"/>
        <NamedIndividual IRI="#Patient_10"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">male</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_age"/>
        <NamedIndividual IRI="#Patient_11"/>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">72</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_gender"/>
        <NamedIndividual IRI="#Patient_11"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">male</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_age"/>
        <NamedIndividual IRI="#Patient_12"/>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">72</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_gender"/>
        <NamedIndividual IRI="#Patient_12"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">male</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_age"/>
        <NamedIndividual IRI="#Patient_2"/>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">73</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_gender"/>
        <NamedIndividual IRI="#Patient_2"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">male</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_age"/>
        <NamedIndividual IRI="#Patient_3"/>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">70</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_gender"/>
        <NamedIndividual IRI="#Patient_3"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">male</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_age"/>
        <NamedIndividual IRI="#Patient_5"/>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">77</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_gender"/>
        <NamedIndividual IRI="#Patient_5"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">male</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_age"/>
        <NamedIndividual IRI="#Patient_6"/>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">66</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_gender"/>
        <NamedIndividual IRI="#Patient_6"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">female</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_age"/>
        <NamedIndividual IRI="#Patient_7"/>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">78</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_gender"/>
        <NamedIndividual IRI="#Patient_7"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">male</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_age"/>
        <NamedIndividual IRI="#Patient_8"/>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">82</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_gender"/>
        <NamedIndividual IRI="#Patient_8"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">male</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_age"/>
        <NamedIndividual IRI="#Patient_9"/>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">57</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_gender"/>
        <NamedIndividual IRI="#Patient_9"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">female</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_reporter_type"/>
        <NamedIndividual IRI="#Report_1"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">physician</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:refers_to_dechallenge_outcome"/>
        <NamedIndividual IRI="#Report_1"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">positive - condition not applied</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:refers_to_outcome_after_action"/>
        <NamedIndividual IRI="#Report_1"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">recovery with no further information</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:refers_to_rechallenge_outcome"/>
        <NamedIndividual IRI="#Report_1"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">negative rechallenge - condition not appeared</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_reporter_type"/>
        <NamedIndividual IRI="#Report_10"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">study</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:refers_to_dechallenge_outcome"/>
        <NamedIndividual IRI="#Report_10"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">positive - condition not applied</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_reporter_type"/>
        <NamedIndividual IRI="#Report_11"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">pharmacist</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:refers_to_dechallenge_outcome"/>
        <NamedIndividual IRI="#Report_11"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">positive - condition not applied</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:refers_to_outcome_after_action"/>
        <NamedIndividual IRI="#Report_11"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">recovery after drug withdrawal</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_reporter_type"/>
        <NamedIndividual IRI="#Report_12"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">physician</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:refers_to_dechallenge_outcome"/>
        <NamedIndividual IRI="#Report_12"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">positive - condition not applied</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:refers_to_outcome_after_action"/>
        <NamedIndividual IRI="#Report_12"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">recovery with no further information</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:refers_to_rechallenge_outcome"/>
        <NamedIndividual IRI="#Report_12"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">negative rechallenge - condition not appeared</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_reporter_type"/>
        <NamedIndividual IRI="#Report_2"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">clinical trial report</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_reporter_type"/>
        <NamedIndividual IRI="#Report_3"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">health care professional, other than physician</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:refers_to_dechallenge_outcome"/>
        <NamedIndividual IRI="#Report_3"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">positive - condition not applied</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_reporter_type"/>
        <NamedIndividual IRI="#Report_4"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">study</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:refers_to_outcome_after_action"/>
        <NamedIndividual IRI="#Report_4"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">death</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_reporter_type"/>
        <NamedIndividual IRI="#Report_5"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">patient</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_reporter_type"/>
        <NamedIndividual IRI="#Report_5"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">physician</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:refers_to_dechallenge_outcome"/>
        <NamedIndividual IRI="#Report_5"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">positive - condition not applied</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_reporter_type"/>
        <NamedIndividual IRI="#Report_6"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">health care professional, other than physician</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:refers_to_outcome_after_action"/>
        <NamedIndividual IRI="#Report_6"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">death</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_reporter_type"/>
        <NamedIndividual IRI="#Report_7"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">patient</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_reporter_type"/>
        <NamedIndividual IRI="#Report_7"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">physician</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:refers_to_dechallenge_outcome"/>
        <NamedIndividual IRI="#Report_7"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">positive - condition not applied</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:refers_to_outcome_after_action"/>
        <NamedIndividual IRI="#Report_7"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">recovery after drug withdrawal</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_reporter_type"/>
        <NamedIndividual IRI="#Report_8"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">study</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:refers_to_dechallenge_outcome"/>
        <NamedIndividual IRI="#Report_8"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">positive - condition not applied</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:refers_to_outcome_after_action"/>
        <NamedIndividual IRI="#Report_8"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">recovery after drug withdrawal</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_reporter_type"/>
        <NamedIndividual IRI="#Report_9"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">physician</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:refers_to_dechallenge_outcome"/>
        <NamedIndividual IRI="#Report_9"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">positive - condition not applied</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:refers_to_outcome_after_action"/>
        <NamedIndividual IRI="#Report_9"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">recovery after drug withdrawal</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_content"/>
        <NamedIndividual IRI="#Reports_in_VigiBase"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">Indication for treatment was reported as CLL in 26 cases, MCL in 7 cases and WM, other specified lymphomas or not given in 4 cases.

Dosages when reported were usually the labelled ones, i.e. 420 or 560 mg daily. The ibrutinib SmPC gives standardized advice for dose reductions in cases of interaction or toxicity. 1 Dose reductions were reported during treatment in a few cases, presumably for interactions or toxicity reasons prior to, or at the time of onset or diagnosis of pneumonitis, although in most reports there is only scant information on the reasons for the dosing revisions.

The recording of any exact time to onset (TTO) would not be expected for any case of pneumonitis due to the natural course of a disease with an often insidious onset. Data on the TTO or time to diagnosis (D) or time to hospitalisation (H) is available with varying degrees of accuracy in most of the reports (n=32). Where there is uncertainty regarding the data, the longest period has been assumed and presented. The range of the TTO/D/H is 2 weeks to 14.5 months with a median of less than 6 months. In eight cases the TTO/D/H was 2 months or less and in three cases the TTO/D/H was 9 months or more.

Only a few reports mention in any detail the diagnostic laboratory methods used. Among methods mentioned are X-ray/CT scan, bronchoscopy, biopsy, BAL and (negative) cultures.

In five cases the outcome was fatal, and in most of these the cause of death was considered by reporters or concluded from the report to be a combination of the reported event(s) and the underlying disease, which would be expected considering the diseases being treated. The pattern of TTO in these cases were similar to the cases in general. Other contributing causes of death in these cases were described as a history of recurrent pneumonitis, sepsis (n=2), cerebral haemorrhage and a “general infective state”.

In 16 reports a dechallenge is mentioned before recovery. Many of the reports mention treatment with antibiotics apparently under following a primary diagnosis of pneumonia with fewer mentioning steroid treatment or a need for oxygen treatment for any period of time. Among the reports from Italy, a translation or coding issue cannot be excluded where the coded (English) MedDRA term pneumonitis in Italian could potentially include both pneumonitis and pneumonia (“polmonite”). When clinically detecting and diagnosing pneumonitis, a primary (differential) diagnosis of pneumonia is common and sometimes the two conditions coincide. From the limited data provided, none of the cases could be definitively excluded as being cases of pneumonia rather than pneumonitis, although in some of them this could be suspected.

Four of the reports include information about a negative rechallenge i.e. where ibrutinib was reinstated with the same (and in some cases a lower) dose without recurrence of the pneumonitis, in some cases with concurrent steroid treatment.

In two of the cases the reporter considered that the underlying disease, rather than ibrutinib, was the more probable cause of the event, which would explain the reaction. In the other two cases, the discovery of pneumonitis appeared to have been a more or less incidental finding, via X-ray and CT respectively, and both of these patients also had a history of several courses of chemotherapy and radiation therapy of the chest, which could have influenced the finding.

Two reports were considered less relevant. They recorded reactions other than pneumonitis in relation to ibrutinib where the patient rather had a history of pneumonitis caused by another drug, apparently mistakenly being coded as a “current” ADR. Another report has been considered “invalid” by the national centre since it only states that the patient “may” have had an ADR and lacks adequate information.

In 11 of the reports, ibrutinib was the only reported drug and in 22 cases it was the only suspected drug. In five cases other drugs were reported alongside ibrutinib for which pneumonitis (or ILD) is mentioned in their respective SmPCs as an acknowledged side effect and which may have contributed to or caused the event. Rituximab, everolimus and/or bendamustine were reported as co-suspect drugs, while mesalazine and filgrastim were reported as concomitant drugs. 2-6 Details on when these drugs were started or stopped in relation to the events were not provided. The concomitant use of these drugs does not preclude a causal role for ibrutinib as a sole causal agent or it having an interactive or additive effect, but of course renders causality assessment from ibrutinib more difficult.

Apart from these 39 reported cases of pneumonitis there are also seven cases of the closely related condition ILD reported for ibrutinib in VigiBase. These cases are not described in detail in this signal review, but do show a similar pattern to the cases reported with pneumonitis.

Table 1 presents the cases which provide the best evidence of a causal relationship between ibrutinib and pneumonitis where investigation results, clinical course and lack of reference to antibacterial use support a diagnosis of non-infective pneumonitis.</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="oa#:exact"/>
        <NamedIndividual IRI="#Selector_1"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">for the majority of other PKI substances, a causal association between the drugs and pneumonitis or similar respiratory drug reactions, is acknowledged and labelled.</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="oa#:prefix"/>
        <NamedIndividual IRI="#Selector_1"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">Ibrutinib is an antineoplastic substance belonging to
the class of protein kinase inhibitors (PKI) where,</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="oa#:suffix"/>
        <NamedIndividual IRI="#Selector_1"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">In May 2016, 39 cases of pneumonitis in relation to
ibrutinib use had been reported by the countries</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_content"/>
        <NamedIndividual IRI="#Summary"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">Ibrutinib is an antineoplastic substance belonging to the class of protein kinase inhibitors (PKI) where, for the majority of other PKI substances, a causal association between the drugs and pneumonitis or similar respiratory drug reactions, is acknowledged
and labelled. 
In May 2016, 39 cases of pneumonitis in relation to ibrutinib use had been reported by the countries participating in the WHO Programme for International Drug Monitoring. An evaluation of the reports of pneumonitis in the WHO global database of individual case safety reports, VigiBase, and other data has been performed. Based on the
available information, the consistent pattern of the events described in the reports, and our background knowledge of the acknowledged
potential of the drug class of PKIs to cause pneumonitis or interstitial lung disease, our conclusion is that for ibrutinib a causal association
between the substance and pneumonitis may also exist. We hence consider this signal worth communicating so that relevant stakeholders may act upon it.</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_content"/>
        <NamedIndividual IRI="#ibrutinib_ADR_mechanism"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">inhibiting signal transduction pathways enhances expression of pro-
inflammatory cytokines and the innate immune system. BTK also appears to serve as a critical mediator of lipopolysaccharide-induced dendritic cell maturation and macrophage polarization. Several studies have reported an increase in alveolar infiltration of T helper 2 pro-inflammatory cytokines in BTK-deficient mice, resulting in
airway inflammation</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_content"/>
        <NamedIndividual IRI="#ibrutinib_mechanism"/>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#gYearMonth">Ibrutinib is a small-molecule inhibitor of Bruton’s tyrosine kinase (TK). It belongs to the rapidly growing and evolving class of functionally diverse approved protein kinase inhibiting (PKI) drugs. Ibrutinib is currently the only substance with its particular mechanism of action approved for use in humans, although we understand there are others under development. Bruton’s TK is a signalling molecule within the B-cell antigen receptor (BCR) and cytokine receptor pathways necessary for B-cell trafficking, chemotaxis and adhesion. The BCR pathway is implicated in several B-cell malignancies, and ibrutinib
inhibits malignant B-cell proliferation and survival. 1 The ATC code is L01XE27.</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_content"/>
        <NamedIndividual IRI="#ibrutinib_metabolism"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">Ibrutinib is primarily metabolised by cytochrome P450 enzyme 3A4 and co-administration with subsequent interaction with strong or moderate CYP3A4 inhibitors may lead to higher toxicity and is hence discouraged in the SmPC.</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty IRI="http://www.w3.org/2006/time#days"/>
        <NamedIndividual IRI="#one_day_interval_between_administrations"/>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">1</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty IRI="http://www.w3.org/2006/time#days"/>
        <NamedIndividual IRI="#onset_time_for_report_11"/>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">20</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty IRI="http://www.w3.org/2006/time#weeks"/>
        <NamedIndividual IRI="#onset_time_for_report_12"/>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">2</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty IRI="http://www.w3.org/2006/time#months"/>
        <NamedIndividual IRI="#onset_time_for_report_2"/>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#decimal">1.5</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty IRI="http://www.w3.org/2006/time#months"/>
        <NamedIndividual IRI="#onset_time_for_report_3"/>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">5</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty IRI="http://www.w3.org/2006/time#months"/>
        <NamedIndividual IRI="#onset_time_for_report_4"/>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">7</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty IRI="http://www.w3.org/2006/time#months"/>
        <NamedIndividual IRI="#onset_time_for_report_5"/>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#decimal">3.5</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty IRI="http://www.w3.org/2006/time#months"/>
        <NamedIndividual IRI="#onset_time_for_report_7"/>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">3</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty IRI="http://www.w3.org/2006/time#months"/>
        <NamedIndividual IRI="#onset_time_for_report_9"/>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">9</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:concerns_action_upon_adverse_effect"/>
        <NamedIndividual IRI="#reports_dechallenged_having_recovery_as_outcome"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">discontinued</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_count"/>
        <NamedIndividual IRI="#reports_dechallenged_having_recovery_as_outcome"/>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">16</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:refers_to_outcome_after_action"/>
        <NamedIndividual IRI="#reports_dechallenged_having_recovery_as_outcome"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">recovery after drug withdrawal</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_count"/>
        <NamedIndividual IRI="#reports_from_Germany"/>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">3</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_count"/>
        <NamedIndividual IRI="#reports_from_Italy"/>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">14</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_count"/>
        <NamedIndividual IRI="#reports_from_UK"/>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">2</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_count"/>
        <NamedIndividual IRI="#reports_from_USA"/>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">20</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_count"/>
        <NamedIndividual IRI="#reports_having_CLL_as_indication"/>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">26</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_count"/>
        <NamedIndividual IRI="#reports_having_MCL_as_indication"/>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">7</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_count"/>
        <NamedIndividual IRI="#reports_having_fatal_outcome"/>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">5</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:refers_to_outcome_after_action"/>
        <NamedIndividual IRI="#reports_having_fatal_outcome"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">death</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_count"/>
        <NamedIndividual IRI="#reports_having_ibrutinib_as_primary_suspect_drug"/>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">22</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:has_count"/>
        <NamedIndividual IRI="#reports_with_negative_rechallenge"/>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">4</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:refers_to_rechallenge_outcome"/>
        <NamedIndividual IRI="#reports_with_negative_rechallenge"/>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">negative rechallenge - condition not appeared</Literal>
    </DataPropertyAssertion>
    <DataPropertyAssertion>
        <DataProperty abbreviatedIRI="open-pv:initially_identified_on"/>
        <NamedIndividual IRI="#signal_in_the_report"/>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#gYearMonth">2016-03</Literal>
    </DataPropertyAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ATC_code"/>
        <IRI>#Acetylsalicylic_Acid</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">B01AC06</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ATC_code"/>
        <IRI>#Aciclovir</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">D06BB03</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ATC_code"/>
        <IRI>#Aciclovir</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">J05AB01</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ATC_code"/>
        <IRI>#Aciclovir</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">J05AB11</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ATC_code"/>
        <IRI>#Aciclovir</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">S01AD03</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ICD_code"/>
        <IRI>#Acute_Respiratory_Distress_Syndrome</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">J80</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_code"/>
        <IRI>#Acute_Respiratory_Distress_Syndrome</IRI>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">10001052</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_prefered_term"/>
        <IRI>#Acute_Respiratory_Distress_Syndrome</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">Acute respiratory distress syndrome</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ICD_code"/>
        <IRI>#Acute_kidney_injure</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">N17.9</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_code"/>
        <IRI>#Acute_kidney_injure</IRI>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">10069339</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_prefered_term"/>
        <IRI>#Acute_kidney_injure</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">Acute kidney injury</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ATC_code"/>
        <IRI>#Allopurinol</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">M04AA01</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ATC_code"/>
        <IRI>#Aminophylline</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">R03DA05</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ATC_code"/>
        <IRI>#Amlodipine</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">C08CA01</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ICD_code"/>
        <IRI>#Anemia</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">D64.9</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_code"/>
        <IRI>#Anemia</IRI>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">10002272</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_prefered_term"/>
        <IRI>#Anemia</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">Anemia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="oa#:hasBody"/>
        <IRI>#Annotation_for_warning_regarding_pkis_and_pneumonitis</IRI>
        <IRI>#pkis_and_pneumonitis</IRI>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="oa#:hasTarget"/>
        <IRI>#Annotation_for_warning_regarding_pkis_and_pneumonitis</IRI>
        <AnonymousIndividual nodeID="_:genid13788"/>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_code"/>
        <IRI>#Arthralgia</IRI>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">10003239</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_code"/>
        <IRI>#Arthralgia</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">M25.50</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_prefered_term"/>
        <IRI>#Arthralgia</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">Arthralgia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ICD_code"/>
        <IRI>#Atrial_Fibrillation</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">I48.9</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_code"/>
        <IRI>#Atrial_Fibrillation</IRI>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">10003658</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_prefered_term"/>
        <IRI>#Atrial_Fibrillation</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">Atrial fibrillation</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ATC_code"/>
        <IRI>#Bendamustine</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">L01AA09</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ICD_code"/>
        <IRI>#Bone_pain</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">M89.9</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_code"/>
        <IRI>#Bone_pain</IRI>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">10006002</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_prefered_term"/>
        <IRI>#Bone_pain</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">Bone pain</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_code"/>
        <IRI>#Cardiotoxicity</IRI>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">10048610</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_prefered_term"/>
        <IRI>#Cardiotoxicity</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">Cardiotoxicity</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ATC_code"/>
        <IRI>#Chloramphenicol</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">D06AX02</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ATC_code"/>
        <IRI>#Chloramphenicol</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">D10AF03</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ATC_code"/>
        <IRI>#Chloramphenicol</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">G01AA05</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ATC_code"/>
        <IRI>#Chloramphenicol</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">J01BA01</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ATC_code"/>
        <IRI>#Chloramphenicol</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">S01AA01</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ATC_code"/>
        <IRI>#Chloramphenicol</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">S02AA01</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ATC_code"/>
        <IRI>#Chloramphenicol</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">S03AA08</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ATC_code"/>
        <IRI>#Colecalciferol</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">A11CC05</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ICD_code"/>
        <IRI>#Congestive_cardiac_failure</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">I50.40</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_code"/>
        <IRI>#Congestive_cardiac_failure</IRI>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">10010682</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_prefered_term"/>
        <IRI>#Congestive_cardiac_failure</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">Congestive cardiac failure</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ICD_code"/>
        <IRI>#Cough</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">R05</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_code"/>
        <IRI>#Cough</IRI>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">10011224</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_prefered_term"/>
        <IRI>#Cough</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">Cough</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ICD_code"/>
        <IRI>#Diarrhea</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">R19.7</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_code"/>
        <IRI>#Diarrhea</IRI>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">10012735</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_prefered_term"/>
        <IRI>#Diarrhea</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">Diarrhoea</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ICD_code"/>
        <IRI>#Electrolyte_disturbances</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">E87.8</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_code"/>
        <IRI>#Electrolyte_disturbances</IRI>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">10061014</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_prefered_term"/>
        <IRI>#Electrolyte_disturbances</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">Blood electrolytes abnormal</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ATC_code"/>
        <IRI>#Enoxaparin</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">B01AB05</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ATC_code"/>
        <IRI>#Erythropoietin</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">B03XA01</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ATC_code"/>
        <IRI>#Ezetimibe</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">C10AX09</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ICD_code"/>
        <IRI>#Fatigue</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">R53.83</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_code"/>
        <IRI>#Fatigue</IRI>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">10016256</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_prefered_term"/>
        <IRI>#Fatigue</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">Fatigue</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ATC_code"/>
        <IRI>#Filgrastim</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">L03AA02</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ICD_code"/>
        <IRI>#Follicular_lymphoma</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">C82</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ATC_code"/>
        <IRI>#Furosemide</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">C03CA01</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_code"/>
        <IRI>#Hepatotoxicity</IRI>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">10019851</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_prefered_term"/>
        <IRI>#Hepatotoxicity</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">Hepatotoxicity</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ICD_code"/>
        <IRI>#Hypertension</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">I10</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_code"/>
        <IRI>#Hypertension</IRI>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">10020772</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_prefered_term"/>
        <IRI>#Hypertension</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">Hypertension</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ATC_code"/>
        <IRI>#Ibrutinib</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">L01XE27</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ATC_code"/>
        <IRI>#Insulin</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">A10A</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ATC_code"/>
        <IRI>#Levothyroxine</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">H03AA01</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ATC_code"/>
        <IRI>#Metformin</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">A10BA02</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ATC_code"/>
        <IRI>#Metoprolol</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">C07AB02</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ICD_code"/>
        <IRI>#Muscle_spasms</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">M62.838</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ICD_code"/>
        <IRI>#Muscle_spasms</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">Muscle spasms</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_code"/>
        <IRI>#Muscle_spasms</IRI>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">10028334</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ICD_code"/>
        <IRI>#Myalgia</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">M79.1</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_code"/>
        <IRI>#Myalgia</IRI>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">10028411</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_prefered_term"/>
        <IRI>#Myalgia</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">Myalgia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ICD_code"/>
        <IRI>#Nasopharyngitis</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">J00</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_code"/>
        <IRI>#Nasopharyngitis</IRI>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">10028810</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_prefered_term"/>
        <IRI>#Nasopharyngitis</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">Nasopharyngitis</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ICD_code"/>
        <IRI>#Nausea</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">R11.0</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_code"/>
        <IRI>#Nausea</IRI>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">10028813</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_prefered_term"/>
        <IRI>#Nausea</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">Nausea</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ATC_code"/>
        <IRI>#Nifedipine</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">C08CA05</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ATC_code"/>
        <IRI>#Oxycodone</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">N02AA05</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ATC_code"/>
        <IRI>#Pantoprazole</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">A02BC02</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ICD_code"/>
        <IRI>#Peripheral_swelling</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">R22.43</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_code"/>
        <IRI>#Peripheral_swelling</IRI>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">10048959</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_prefered_term"/>
        <IRI>#Peripheral_swelling</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">Peripheral swelling</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ATC_code"/>
        <IRI>#Pioglitazone</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">A10BG03</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ICD_code"/>
        <IRI>#Pleural_effusion</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">J90</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_code"/>
        <IRI>#Pleural_effusion</IRI>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">10035598</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_prefered_term"/>
        <IRI>#Pleural_effusion</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">Pleural effusion</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ICD_code"/>
        <IRI>#Pneumonia</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">J15</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_code"/>
        <IRI>#Pneumonia</IRI>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">10035664</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_prefered_term"/>
        <IRI>#Pneumonia</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">Pneumonia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ICD_code"/>
        <IRI>#Pneumonitis</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">J67.9</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_code"/>
        <IRI>#Pneumonitis</IRI>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">10035742</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_prefered_term"/>
        <IRI>#Pneumonitis</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">Pneumonitis</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ATC_code"/>
        <IRI>#Prednisone</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">A07EA03</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ATC_code"/>
        <IRI>#Prednisone</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">H02AB07</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ICD_code"/>
        <IRI>#Pulmonary_fibrosis</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">J84.10</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_code"/>
        <IRI>#Pulmonary_fibrosis</IRI>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">10037383</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_prefered_term"/>
        <IRI>#Pulmonary_fibrosis</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">Pulmonary fibrosis</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ICD_code"/>
        <IRI>#Pyrexia</IRI>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#decimal">075.2</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_code"/>
        <IRI>#Pyrexia</IRI>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">10037660</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_prefered_term"/>
        <IRI>#Pyrexia</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">Pyrexia</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:comment"/>
        <IRI>#Report_1</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">CLL, physician report, non-smoker, heavily pre-treated, diagnosis confirmed via CT, treatment with steroids, assessed as related</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:comment"/>
        <IRI>#Report_10</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">diagnosis via signs, symptoms and typical X-ray findings. No data on previous lines of treatment. Treated with steroids, cyclophosphamide, oxygen. Recovered. Rechallenge was considered but was not performed as the patient developed AML. Timing of filgrastim not provided in detail.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:comment"/>
        <IRI>#Report_11</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">sparse information, treatment with posaconazole</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:comment"/>
        <IRI>#Report_12</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">MCL/CLL (MCL disease progression w leukemic course), physician study report, 2 previous lines of treatment, diagnosis confirmed via CT, BAL negative, recovered from pneumonia with antibiotics, recovered from pneumonitis with steroids and oxygen, study drug successfully rechallenged with concomitant steroid</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:comment"/>
        <IRI>#Report_2</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">patient presenting after 39 days with fatigue and fever, chest x-ray showing pneumonitis; antibiotics started, open biopsy confirmation of pneumonitis with negative cultures, acute respiratory failure with ICU treatment, assessed as related to ibrutinib or possibly to infection but not to rituximab or underlying disease</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:comment"/>
        <IRI>#Report_3</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">diagnosis confirmed via CT and chest X-ray. treated with decreasing amounts of oxygen after withdrawal of drug. Superimposed pneumonia.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:comment"/>
        <IRI>#Report_4</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">ARDS during cycle 8, bronchoscopy culture positive for rhinovirus, grade 5 rhinovirus infection. Treated with broad spectrum antibiotics and high dose steroids</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:comment"/>
        <IRI>#Report_5</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">non-smoker, diagnosis of pneumonitis confirmed via CT, treated with antibiotics, causality assessed as related, patient restarted on idelalisib and rituximab.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:comment"/>
        <IRI>#Report_6</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">ex-smoker, two previous lines of therapy, death due to disease progression and reported reactions, sepsis assessed as not related to ibrutinib, no causality assessment for pneumonitis provided</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:comment"/>
        <IRI>#Report_7</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">ex-smoker, differing information. History includes GERD, diabetes, arrhythmia, arthritis, heart disease, recurrent pneumonia, several previous lines of CLL treatment including rituximab, IVIG, cyclophosphamide, fludara.

After one month of ibrutinib onset of musculoskeletal problems, fatigue. Dose decreased with positive effect. Dose re-increased with recurring fatigue, shortness of breath, cough and ultimately a pneumonitis diagnosis confirmed via chest X-ray.

Dose decreased with some positive effect but ultimately ibrutinib
withdrawal. Reinstating ibrutinib was discussed but no definite
information.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:comment"/>
        <IRI>#Report_8</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">Presented hypoxic but without respiratory complaints after a fall with a scapula fracture. X-ray and CT scan findings suspicion of atypical infection from immunosuppression. Rapid deterioration and ICU treatment with mechanical ventilation. Absence of response to antibiotics, negative cultures, raised CRP, SR and low procalcitonin raises suspicion of inflammatory pneumonitis. Biopsy and BAL consistent with diagnosis. Rapid improvement on steroids after discontinuation of drug. Ibrutinib considered only identifiable agent.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:comment"/>
        <IRI>#Report_9</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">treated on a named patient programme continuing after programme stopped, previous treatment including rituximab and bendamustine 4 years prior to event, history of bronchial asthma, pneumonitis detected by CT, rechallenge negative with reduced dose (six months follow up)</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Reports_in_VigiBase</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">Reports in VigiBase</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ICD_code"/>
        <IRI>#Respiratory_failure</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">J96</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_code"/>
        <IRI>#Respiratory_failure</IRI>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">10038695</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_prefered_term"/>
        <IRI>#Respiratory_failure</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">Respiratory failure</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ICD_code"/>
        <IRI>#Rhinovirus_infection</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">B34.8</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_code"/>
        <IRI>#Rhinovirus_infection</IRI>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">10061494</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_prefered_term"/>
        <IRI>#Rhinovirus_infection</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">Rhinovirus infection</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ATC_code"/>
        <IRI>#Rituximab</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">L01XC02</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ATC_code"/>
        <IRI>#Rosuvastatin</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">C10AA07</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ICD_code"/>
        <IRI>#Sepsis</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">A41</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_code"/>
        <IRI>#Sepsis</IRI>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">10040047</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_prefered_term"/>
        <IRI>#Sepsis</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">Sepsis</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ICD_code"/>
        <IRI>#Sodium_decreased</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">E87.1</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_code"/>
        <IRI>#Sodium_decreased</IRI>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">10041268</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_prefered_term"/>
        <IRI>#Sodium_decreased</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">Sodium decreased</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ICD_code"/>
        <IRI>#Swelling</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">R19.05</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_code"/>
        <IRI>#Swelling</IRI>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">10042674</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_prefered_term"/>
        <IRI>#Swelling</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">Swelling</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ATC_code"/>
        <IRI>#Tamsulosin</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">G04CA02</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_code"/>
        <IRI>#Toxicity</IRI>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#integer">10070863</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_MedDRA_prefered_term"/>
        <IRI>#Toxicity</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">Toxicity to various agents</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ATC_code"/>
        <IRI>#Tranexamic_acid</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">B02AA02</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Uppsala_Monitoring_Centre</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">Uppsala Monitoring Centre</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ATC_code"/>
        <IRI>#Valaciclovir</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">J05AB11</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ATC_code"/>
        <IRI>#Warfarin</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">B01AA03</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="oa#:hasBody"/>
        <IRI>#pkis_and_electrolytes</IRI>
        <IRI>#pkis_and_electrolytes</IRI>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="oa#:hasTarget"/>
        <IRI>#pkis_and_electrolytes</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">Other notable side effects in several PKIs are electrolyte disturbances, hypertension, cardiotoxicity, and hepatotoxicity</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#protein_kinase_inhibitors</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">Protein Kinase Inhibitors (PKI)</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ATC_code"/>
        <IRI>#Ω-3-acid</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">C10AX06</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#1._European_Medicines_Agency:_Summary_of_Product_Characteristics_for_ibrutinib_(Imbruvica®)._Available_from:_http://www.ema.europa.eu/docs/en_GB/_document_library/EPAR_-_Product_Information/_human/003791/WC500177775.pdf._Accessed:_September_2016.</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">1. European Medicines Agency: Summary of Product Characteristics for ibrutinib (Imbruvica®). Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003791/WC500177775.pdf. Accessed: September 2016.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#2._European_Medicines_Agency:_Summary_of_Product_Characteristics_for_rituximab_(MabThera®)._Available_from:_http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000165/WC500025821.pdf._Accessed:_October_2016.</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">2. European Medicines Agency: Summary of Product Characteristics for rituximab (MabThera®). Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000165/WC500025821.pdf. Accessed: October 2016.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#3._European_Medicines_Agency:_Summary_of_Product_Characteristics_for_everolimus_(Afinitor®)._Available_from:_http://www.ema.europa.eu/docs/en_GB/_document_library/EPAR_-_Product_Information/_human/001038/WC500022814.pdf._Accessed:_October_2016.</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">3. European Medicines Agency: Summary of Product Characteristics for everolimus (Afinitor®). Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001038/WC500022814.pdf. Accessed: October 2016.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#4._US_Food_and_Drug_Administration:_Product_label_for_bendamustine_(Treanda®)._Available_from:_http://www.accessdata.fda.gov/drugsatfda__docs/label/2016/022249s022lbl.pdf._Accessed:_October_2016.</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">4. US Food and Drug Administration: Product label for bendamustine (Treanda®). Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022249s022lbl.pdf. Accessed: October 2016.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#5._Electronic_Medicines_Compendium:_Summary_of_Product_Characteristics_for_mesalazine_(Asacol®)._Available_from:_https://www.medicines.org.uk/emc/_medicine/20478._Accessed:_October_2016.</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">5. Electronic Medicines Compendium: Summary of Product Characteristics for mesalazine (Asacol®). Available from: https://www.medicines.org.uk/emc/medicine/20478. Accessed: October 2016.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#6._Electronic_Medicines_Compendium:_Summary_of_Product_Characteristics_for_filgrastim_(Neupogen®)._Available_from:_https://www.medicines.org.uk/emc/_medicine/27485._Accessed:_October_2016.</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">6. Electronic Medicines Compendium: Summary of Product Characteristics for filgrastim (Neupogen®). Available from: https://www.medicines.org.uk/emc/medicine/27485. Accessed: October 2016.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#7._Mato_AR,_Islam_P,_Daniel_C,_Strelec_L,_Kaye_AH,_Brooks_S,_et_al._Ibrutinib-induced_pneumonitis_in_patients_with_chronic_lymphocytic_leukemia._Blood,_2016._Feb_25;127(8):1064-7.</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">7. Mato AR, Islam P, Daniel C, Strelec L, Kaye AH, Brooks S, et al. Ibrutinib-induced pneumonitis in patients with chronic lymphocytic leukemia. Blood, 2016. Feb 25;127(8):1064-7.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#8._Shah_RR._Tyrosine_Kinase_Inhibitor-Induced_Interstitial_Lung_Disease:_Clinical_Features,_Diagnostic_Challenges,_and_Therapeutic_Dilemmas._Drug_Saf._2016_Aug_17._[Epub_ahead_of_print].</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">8. Shah RR. Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas. Drug Saf. 2016 Aug 17. [Epub ahead of print].</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#9._Mahmoudi_M,_Murthy_V,_Suh_J,_Bradshaw_A,_Sloance_M._Ibrutinib-Induced_Rapidly_Progressive_Inflammatory_Pneumonitis._American_Thoracic_Society_International_Conference_Abstract,_2015.</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">9. Mahmoudi M, Murthy V, Suh J, Bradshaw A, Sloance M. Ibrutinib-Induced Rapidly Progressive Inflammatory Pneumonitis. American Thoracic Society International Conference Abstract, 2015.</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ICD_code"/>
        <IRI>#Waldenström’s_macroglobulinaemia_(WM)</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">C88.0</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#Waldenström’s_macroglobulinaemia_(WM)</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">Waldenström’s macroglobulinaemia (WM)</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ICD_code"/>
        <IRI>#chronic_lymphatic_leukaemia_(CLL)</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">C91.1</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#chronic_lymphatic_leukaemia_(CLL)</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">chronic lymphatic leukaemia (CLL)</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="open-pv:has_ICD_code"/>
        <IRI>#mantle_cell_lymphoma_(MCL)</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">C83.10</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="rdfs:label"/>
        <IRI>#mantle_cell_lymphoma_(MCL)</IRI>
        <Literal datatypeIRI="http://www.w3.org/1999/02/22-rdf-syntax-ns#PlainLiteral">mantle cell lymphoma (MCL)</Literal>
    </AnnotationAssertion>
    <AnnotationAssertion>
        <AnnotationProperty abbreviatedIRI="oa#:hasSource"/>
        <AnonymousIndividual nodeID="_:genid13789"/>
        <Literal datatypeIRI="http://www.w3.org/2001/XMLSchema#anyURI">http://apps.who.int/iris/bitstream/10665/258799/1/WPN-2017-03-eng.pdf?ua=1</Literal>
    </AnnotationAssertion>
</Ontology>



<!-- Generated by the OWL API (version 4.2.8.20170104-2310) https://github.com/owlcs/owlapi -->

